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ABSTRACT 
THE MOLECULAR BASIS OF SUBSTRATE RECOGNITION BY THE FAMILY OF PELLINO E3 
UBIQUITIN LIGASES 
Yu-San Huoh 
Kathryn M. Ferguson 
The four mammalian Pellinos (Pellinos 1, 2, 3a, and 3b) are E3 ubiquitin ligases that have 
emerging roles in the regulation of Toll-like receptors, interleukin-1 receptor, T-cell receptor, 
Nod2, and TNF receptor signaling pathways. While each Pellino has a distinct role in facilitating 
various cellular processes, the underlying mechanisms by which these highly homologous 
proteins act selectively in these signaling pathways are not clear. In this dissertation, we elucidate 
the molecular basis of Pellino substrate specificity in order to gain a better understanding of the 
roles that individual Pellinos play in orchestrating inflammation and cell death. Pellino substrate 
recognition is mediated by a non-canonical FHA domain, a well-characterized phosphothreonine 
binding module. We identify a high-affinity Pellino-FHA domain binding motif in the Pellino 
substrate, interleukin 1 receptor associated kinase 1 (IRAK1). Binding analysis of the different 
Pellinos to a panel of pT-peptides reveals that each Pellino has a distinct binding specificity. This 
specificity also manifests in the interaction of Pellinos with a number of known Pellino substrates. 
These results argue that the non-redundant roles that Pellinos play in immune signaling are in 
part due to their divergent substrate specificities. In addition to elucidating Pellino substrate 
binding preferences, we also sought to determine how Pellinos interact with substrates. Through 
mutational analyses, we have found that the Pellino2 FHA domain β9/β10 loop mediates 
interactions with IRAK1, but is dispensable for pT-peptide binding. These results show that 
Pellino substrate binding determinants may require more than a short pT-peptide motif.   
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1. Background 
 
1.1. Pellino E3 ubiquitin ligases are critical mediators of innate receptor signaling  
One branch of innate immunity involves host surveillance of pathogens by the arsenal of pattern 
recognition receptors (PRRs). The evolutionarily conserved family of PRRs includes membrane-
bound Toll-like receptors (TLRs) and the cytoplasmic nucleotide oligomerization domain (Nod)-
like receptors (Nod1 and 2) and retinoic-acid-inducible-protein I (RIG-I)-like receptors (RLRs) [1]. 
Upon detecting conserved elements of invading microorganisms known as pathogen associated 
molecular patterns (PAMPS), these PRRs initiate various signaling cascades that culminate in the 
activation of transcription factors, such as nuclear factor-kappaB (NF-κB) and interferon regulator 
factors (IRFs) [1-3], which up-regulate the synthesis and secretion of proinflammatory cytokines, 
chemokines, and interferons [1]. Regulation of PRR signaling networks relies heavily on carefully 
orchestrated phosphorylation and ubiquitination of the numerous signaling components.  
Ubiquitination involves the covalent attachment of a 76 amino acid protein, ubiquitin, to a 
target protein [1,4]. This process involves the sequential actions of three ubiquitin ligases: first, 
the E1 ubiquitin-activating enzyme forms an ATP-dependent thioester bond between the C-
terminus of ubiquitin and a cysteine within the E1 active-site; activated ubiquitin is then 
transferred to the active site cysteine of an E2 ubiquitin-conjugating (Ubc) enzyme; finally, an E3 
ubiquitin-protein ligase facilitates the transfer of ubiquitin from the E2 enzyme to a lysine on the 
target protein [2-4]. Once a target protein is monoubiquitinated, the ubiquitin attached to the 
target can also undergo ubiquitination via one of its seven lysine residues [1,4] or N-terminus [5]. 
This leads to the formation of polyubiquitin chains on a target protein, where the type of ubiquitin 
linkage determines the biological function of the protein. For example, K48-linked 
polyubiquitination marks a protein for proteasomal degradation; on the other hand, K63-linked 
polyubiquitination marks proteins for non-degradative processes including the formation of 
signaling complexes and activation of protein kinases [6]. Like phosphorylation, ubiquitination is a 
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post-translational modification that is required for facilitating a variety of cellular processes. My 
dissertation focuses on the role of an E3 ubiquitin ligase family Pellino that mediates 
ubiquitination events in the context of innate immune signaling pathway regulation. 
The Pellinos are one of several families of E3 ubiquitin ligases that have emerging roles 
in facilitating TLR and Nod2-dependent NF-κB and IRF3/7 activation [7-10]. The family of Pellinos 
includes 4 mammalian isoforms: Pellino1, 2, and splice variants 3a and 3b. Although Pellinos 
were originally thought to simply be adaptor proteins that are recruited upon TLR and interleukin-
1 receptor (IL-1R) stimulation, sequence analysis and in vitro ubiquitination assays identified that 
all mammalian Pellino isoforms are catalytically active RING E3 ubiquitin ligases that are able to 
form K48 and K63-ubiquitin linkages [11-13]. Here, we describe what is currently known about 
how Pellinos regulate these innate immune receptor signaling pathways (summarized in Figure 
1.1A).  
1.1.1. The role of Pellinos in TLR/IL-1R signaling 
The Toll/IL-1R (TIR) superfamily comprises of the TLRs (numbered 1-10 and 1-12 in humans and 
mice, respectively) and IL-1R [14]. Each TIR member contains a cytoplasmic TIR domain that 
maintains homotypic interactions with adaptor proteins that also contain TIR domains [14]. Upon 
receptor stimulation, IL-1R and all TLRs, except for TLR3, can interact with the adaptor protein 
myeloid differentiation factor 88 (MyD88) to recruit and activate the family of interleukin-1 receptor 
(IL-1R) associated kinases (IRAKs) [2]. Recruited IRAKs subsequently trigger downstream 
signaling networks that lead to the activation of NF-κB, and IRF7, along with the mitogen-
activated protein kinases (MAPKs) [2]. TLR3 and also TLR4 alternatively recruit the adaptor 
molecule TRIF (TIR-domain-containing adaptor-inducing interferon-β), which targets TANK-
binding kinase 1 (TBK1) and RIP1 (receptor-interacting serine/threonine-protein kinase) in order 
to activate NF-κB and IRF3/7, and MAPK signaling pathways [2,15]. 
Pellinos play a crucial role in directing polyubiquitination events immediately following 
TLR/IL-1R stimulation [16-18]. For example, Pellino2 is implicated in the IL-1-dependent K63-
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linked polyubiquitination of IRAK1 [18], which is a requirement for the activation of inhibitor of κB 
kinase (IKK) complex that allows for NF-κB to translocate into the nucleus [19,20]. By contrast, 
Pellino1 and 3 knockout mice studies show that both Pellinos are dispensable for NF-κB 
activation in IL-1R signaling [17,21]. Instead, Pellino1 mediates RIP1 polyubiquitination, which is 
required for NF-κB activation in TRIF-dependent TLR 3/4 signaling pathways [17]. In addition, 
Pellino1 E3 ligase activity is critical for the activation of type I interferon expression in the same 
TRIF-dependent signaling pathways, although Pellino1-mediated RIP1 polyubiquitination is not 
required for this process [22]. On the other hand, Pellino3 does not activate TLR3/4-mediated NF-
κB signaling, but instead modulates TLR3-mediated IRF7 activation [21]. Upon TLR3 stimulation, 
Pellino3 interacts with and polyubiquitinates the E3 ubiquitin ligase tumor necrosis factor receptor 
associated factor 6 (TRAF6); this modification prevents TRAF6 association with IRF7, which 
ultimately suppresses the TLR3-induction of type I interferon expression [21].  
1.1.2. The role of Pellino3 in Nod2 signaling  
Nod-like receptors (Nod1 and 2) are cytoplasmic PRRs that recognize peptides derived from 
bacterial peptidoglycans [23]. Instead of TIR domains, Nod-like receptors contain caspase-
recruitment domains (CARDs) that directly make homotypic interactions with their cognate 
CARD-containing kinase, RIP2 (also known as RICK) [23]. Upon peptidoglycan-stimulation of 
Nod-like receptors, activated RIP2 interacts with transforming-growth-factor-β-activated kinase 1 
(TAK1) complex, which ultimately leads to the stimulation of signaling pathways similar to TLR 
signaling [23]. Comparable to the IKK complex recognition of Lys63-linked polyubiquitinated 
IRAK1, TAK1 complex association requires Lys63-linked polyubiquitination of RIP2 [24]. Very 
recently, Pellino3 was found to be the E3 ligase that mediates Lys63-polyubquitination of RIP2 
and is a necessary signaling component involved with the activation of Nod2-dependent NF-κB 
signaling pathway [10].  
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1.2 The emerging roles of Pellino in other signaling pathways 
Recent gene targeting studies in mice have revealed new roles for Pellinos in the modulation of 
two processes outside the context of innate immune signaling: T-cell receptor (TCR) and tumor 
necrosis factor-α (TNF) signaling pathways (summarized in Figure 1.1B and C).  
1.2.1. The role of Pellino1 in TCR signaling 
Unlike Pellino2 and 3, Pellino1 is highly expressed in B- and T-cells. Upon further investigation of 
Pellino1’s unique presence in B- and T-cells, it was discovered that Pellino1 surprisingly plays a 
role in maintaining proper T-cell activation [25]. T-cell activation is tightly controlled by the T-cell 
antigen receptor (TCR) and co-stimulatory receptors such as CD28 [26]. The stimulation of 
TCR/CD28 ultimately leads to the robust activation of NF-κB [27]. While Pellino1 up-regulates 
NF-κB signaling in TRIF-dependent TLR3/4 signal transduction [17], Pellino1 down-regulates NF-
κB signaling during TCR stimulation [25]. Pellino1 carries out this functional role by targeting 
cRel, a NF-κB family member that is a critical mediator of T-cell activation [25]. Peli1 appears to 
facilitate the Lys48-linked polyubiquitination of cRel, which marks activated cRel for proteasomal 
degradation [25]. The inhibitory function of Pellino1 on T-cell activation is therefore crucial for 
maintaining self-tolerance and the suppression of autoimmunity.   
1.2.2. The role of Pellino3 in TNF signaling 
TNF is a pro-inflammatory cytokine responsible for mediating inflammation and apoptosis [15]. 
The interaction of TNF with its cognate receptor TNFR1 stimulates the trimerization of the 
receptor and subsequently the recruitment of a membrane-associated complex known as 
Complex I [15]. Complex I is made up of the adaptor protein TNFR1-associated death domain 
(TRADD), RIP1 and several ubiquitin E3 ligases, including TNFR-associated factor 2 (TRAF2), 
and cellular inhibitor of apoptosis proteins (cIAPs) 1 and 2 [15]. The formation of Complex I leads 
to the Lys63-linked polyubiquitination of RIP1, which ultimately activates NF-κB and prevents cell 
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death [15]. Within 10-15 minutes after TNF stimulation, deubiquitylation enzymes A20 and 
cylindromatosis (CYLD) can remove Lys63-linked ubiquitin from RIP1 [15]. This process is known 
as ubiquitin editing, which is loosely defined as the replacement of polyubiquitination chains for 
different polyubiquitination chains that signal the target protein for alternative functional outcomes 
[3]. The ubiquitin editing of RIP1 leaves RIP1 unable to activate NF-κB and associate with TNFR1 
[15]. This then leads to the formation of the pro-apoptotic Complex II (also known as death-
inducing signaling complex, DISC), which includes the adaptor FAS-associated death domain 
protein (FADD), caspase 8 and RIP1 [15]. Complex II formation triggers the activation of caspase 
8, which subsequently initiates a downstream caspase cascade that ultimately leads to cell-death 
[15]. Activated caspase8 can also cleave RIP1 –further dampening the NF-κB signaling pathway 
and augmenting pro-apoptotic signals [15]. 
While Pellino1 mediates RIP1 ubiquitination downstream of TLR3/4-activation [17], 
Pellino3 regulates RIP1, but in the context of TNFR1-activation [28]. In a TNF-dependent manner, 
Pellino3 interacts with RIP1 to impede the formation of Complex II and limit caspase 8-mediated 
cleavage of RIP1 [28]. By contrast, Pellino3 does not interact with RIP1 in Complex I, suggesting 
that Pellino3 does not regulate TNF-mediated NF-κB activation [28]. Thus, Pellino3 is only 
responsible for down-regulating the pro-apoptotic affects of RIP1 activation in TNF-signaling [28]. 
 
1.3. Pellinos’ relevance to inflammatory diseases 
Links between individual Pellinos and the pathogenesis of specific inflammatory diseases have 
also been established. Pellino1 is a critical mediator of microglia activation and contributes to the 
onset of the mouse model for multiple sclerosis, autoimmune encephalomyelitis (EAE) [29]. 
Pellino3 deficiency enhances the pathogenesis of experimental murine models of colitis; this 
correlates with the lower Pellino3 expression levels that are consistently seen in colon samples 
from Crohn’s disease patients [10]. Gaining insight into how Pellinos specifically regulate a variety 
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of immune signaling pathways will therefore also provide a better understanding of the molecular 
basis of these inflammatory diseases.  
 
1.4. Pellino substrate specificity  
1.4.1. Pellino substrate binding domain contains a non-canonical FHA domain 
Previous structural studies of the human Pellino2 substrate-recognition domain revealed an 
unexpected, non-canonical example of a forkhead-associated (FHA) domain (Figure 1.2) [30]. 
The FHA domain is a well-characterized protein interaction module that binds to phosphorylated 
threonine (pT) in the context of a specific recognition sequence [31-35]. Sequence analysis was 
not able to predict the presence of an FHA domain in Pellino because its canonical FHA eleven-
stranded β-sandwich contains two long insertions that form six additional β-strands [30] (Figure 
1.2). These six β-strands form an adjacent subdomain or “wing” appendage that is not seen in 
any other FHA domain structures (see Figure 1.2). Despite the presence of the wing appendage, 
mutational analysis of the Pellino2 FHA domain suggests that Pellino2 association with IRAK1 is 
mediated by Pellino FHA domain recognition of specific pT-peptide sequences on IRAK1 ([30] 
and further described in detail in Chapter 2). The high sequence identity amongst the Pellinos 
suggests that all Pellinos contain FHA domains (Figure 1.3). The identification that Pellinos 
contain FHA domains provides the molecular basis for the IL-1 and TLR ligand-inducible nature of 
the Pellino:IRAK1 interaction [36,37] and its dependence on the phosphorylation of IRAK1 
[11,38].  
The discovery that all Pellinos possess a phospho-binding domain highlights the 
crosstalk that occurs between phosphorylation and ubiquitination events that are crucial for 
coordinating various cellular processes. Other FHA-RING E3 ubiquitin ligases include RING 
finger 8 (RNF8) and Checkpoint with FHA and RING (Chfr), which both serve as cell-cycle 
checkpoint proteins [39]. Phosphorylation-dependent ubiquitination of target proteins is a 
common theme in the kinase-mediated activation of NF-κB [40]. In addition to Pellinos, Skp1-
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Cullin-F-box (SCF) complex E3 ubiquitin ligases also contain phospho-binding modules (such as 
WD40 repeats) that coordinate ubiquitination of substrates upon TLR-stimulation [40,41].  
1.4.2. The Pellino FHA domain is important for immune signaling and cell death 
Studies suggest that Pellino substrate interactions involved in other signaling pathways are 
regulated in a similar manner as the Pellino-IRAK1 association. Pellino3 variants with mutations 
in the FHA-domain pT-peptide binding pocket disrupt both Pellino3-dependent Nod2 and TNF 
signaling events [10,28]. Intriguingly, while both the Pellino3 FHA domain and RING domains are 
necessary for proper Nod2 signaling, the Pellino3-mediated regulation of TNF signaling is only 
dependent on the Pellino3 FHA domain [28]; this implicates that the catalytic activity of Pellino3 is 
dispensable for mediating pro-apoptotic events.  
Viruses have evolved a variety of strategies to target and suppress the host immune 
system. Interestingly, the Melanoplus sanguinipes entomopoxvirus genome contains an open 
reading frame that encodes a viral homolog of Pellino. Viral Pellino is predicted to form a 
canonical FHA domain without the wing appendage or RING domain [42]. This viral Pellino is 
capable of interacting with IRAK1 and can compete with mammalian Pellino3 for IRAK1 
association [42]. Furthermore, viral Pellino is able to inhibit Toll and TLR signal transduction in 
Drosophila S2 cells and HEK293-TLR4 cells, respectively [42]; this suggests that viral Pellino has 
the ability to inhibit host immune responses. The fact that there exists a viral Pellino that can 
hijack the TLR signaling pathway suggests that Pellinos are indeed important mediators of 
immune signaling.  
Clearly, Pellinos have non-redundant and contrasting roles in regulating immune receptor 
signaling and apoptosis. To mediate these various functions, Pellinos interact with a diverse set 
of substrates. However, little is known about how individual members of this highly conserved 
family of E3 ubiquitin ligases [43] selectively act upon components within the TLR, Nod2, TCR, 
and TNFR1 signaling pathways. In this investigation, we elucidate the molecular basis of Pellino 
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substrate specificity in order to gain a better understanding of the roles that individual Pellinos 
play in orchestrating inflammation and cell death. 
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Figure 1.1. Pellino-mediated signaling events downstream of IL-1R/TLR, Nod2, TCR and 
TNFR1 activation.   
(A) The Toll/IL-1R (TIR) superfamily comprises of the TLRs (TLRs 1-10 in humans) and IL-1R. 
Each TIR member contains a cytoplasmic TIR domain that maintains homotypic interactions with 
adaptor proteins that also contain TIR domains. Upon receptor stimulation, IL-1R and all TLRs, 
except for TLR3, can interact with the adaptor protein myeloid differentiation factor 88 (MyD88) to 
recruit and activate the family of interleukin-1 receptor (IL-1R) associated kinases (IRAKs). 
Recruited IRAKs subsequently trigger downstream signaling networks that lead to the activation 
of NF-κB, and IRF7. TLR3 and also TLR4 alternatively recruit the adaptor molecule TRIF (TIR-
domain-containing adaptor-inducing interferon-BETA), which targets TANK-binding kinase 1 
(TBK1) and RIP1 (receptor-interacting S/T-protein kinase) in order to activate NF-κB and IRF3/7, 
and MAPK signaling pathways. Pellinos play a crucial role in directing polyubiquitination events 
immediately following TLR/IL-1R stimulation. For example, Pellino2 is implicated in the IL-1-
dependent K63-linked polyubiquitination of IRAK1, which is a requirement for the activation of 
inhibitor of κB kinase (IKK) complex. By contrast, Pellino1 and Pellino3 are dispensable for NF-
κB activation in IL-1R signaling. Instead, Pellino1 mediates RIP1 polyubiquitination, which is 
required for NF-κB activation in TRIF-dependent TLR 3/4 signaling pathways. In addition, 
Pellino1 E3 ligase activity is critical for the activation of type I interferon expression in the same 
TRIF-dependent signaling pathways, although Pellino1-mediated RIP1 polyubiquitination is not 
required for this process. On the other hand, Pellino3 does not activate TLR3/4-mediated NF-κB 
signaling, but instead modulates TLR3-mediated IRF7 activation. Upon TLR3 stimulation, 
Pellino3 interacts with and polyubiquitinates the E3 ubiquitin ligase tumor necrosis factor receptor 
associated factor 6 (TRAF6); this modification prevents TRAF6 association with IRF7, which 
ultimately suppresses the TLR3-induction of type I interferon expression. The cytoplasmic Nod-
like receptors (Nod1 and 2) contain caspase-recruitment domains (CARDs) that directly make 
homotypic interactions with their cognate CARD-containing kinase, RIP2. Upon ligand-stimulation 
of Nod-like receptors, activated RIP2 interacts with transforming-growth-factor-β-activated kinase 
1 (TAK1) complex, which ultimately leads to the stimulation of signaling pathways similar to TLR 
signaling. Pellino3 is implicated to be the E3 ligase that mediates Lys63-polyubquitination of RIP2 
and is a necessary signaling component involved with the activation of Nod2-dependent NF-κB 
signaling pathway. (B) Pellino1 is critical for maintaining proper T-cell activation. T-cell activation 
is tightly controlled by the T-cell antigen receptor (TCR) and co-stimulatory receptors such as 
CD28. The stimulation of TCR/CD28 ultimately leads to the robust activation of NF-κB. Pellino1 
down-regulates NF-κB signaling during TCR stimulation by targeting cRel, a NF-κB family 
member. Peli1 facilitates the Lys48-linked polyubiquitination of cRel, which marks activated cRel 
for proteasomal degradation. (C) TNF is a pro-inflammatory cytokine responsible for mediating 
inflammation and apoptosis. The interaction of TNF with its cognate receptor TNFR1 stimulates 
the trimerization of the receptor and subsequently the recruitment of a membrane-associated 
complex known as Complex I. Complex I is made up of the adaptor protein TNFR1-associated 
death domain (TRADD), RIP1 and several ubiquitin E3 ligases, including TNFR-associated factor 
2 (TRAF2), and cellular inhibitor of apoptosis proteins (cIAPs) 1 and 2. Complex I formation leads 
to the Lys63-linked polyubiquitination of RIP1, which ultimately activates NF-κB and prevents cell 
death. Within 10-15 minutes after TNF stimulation, deubiquitylation enzymes A20 and 
cylindromatosis (CYLD) can remove Lys63-linked ubiquitin from RIP1. The ubiquitin editing of 
RIP1 leaves RIP1 unable to activate NF-κB and associate with TNFR1. This then leads to the 
formation of the pro-apoptotic Complex II, which includes the adaptor FAS-associated death 
domain protein (FADD), caspase 8 and RIP1 [15]. Complex II formation triggers the activation of 
caspase 8, which subsequently initiates a downstream caspase cascade that ultimately leads to 
cell-death. In a TNF-dependent manner, Pellino3 interacts with RIP1 to impede the formation of 
Complex II and limit caspase 8-mediated cleavage of RIP1. 
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Figure 1.2. The Pellino2 substrate binding domain is a non-canonical FHA domain. 
(A) Cartoon representations of the Pellino2 substrate binding domain structure. The canonical 
FHA core is colored green and the two insertions within the FHA core are highlighted in blue 
(amino acids 51-98 and 159-184 in dark and light blue, respectively). β-strands of the FHA core 
are numbered 1-11, while those of the wing are numbered 1’-6’. The N- and C-termini are 
labeled, as are the amino acids numbers at the beginning and end of each missing loop. (B) 
Schematic representation of the full-length Pellino2 domain architecture. This figure was 
reproduced from [30]. 
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Figure 1.3. Sequence alignment of select mammalian Pellinos 
A sequence alignment of mouse Pellino1 and 3, human Pellino2, 3a and 3b plus two 
representative examples of Pellino3a isoforms from other organisms (chimpanzee and cow). 
Sequences were aligned using Jalview 2.8 [44]. Shading represents percent sequence identity 
with the darkest blue indicating greatest sequence identity. Dots immediately above the sequence 
refer to every 10th amino acid of Pellino1. The 24 amino acid insert in human Pellino3a is 
highlighted in yellow. Structural information from Pellino2-FHA (PDB ID: 3EGA) is shown above 
the sequence. Arrows representing the position of the β-strands are colored in green for those in 
the FHA core and blue for those in the wing appendage. Dotted lines indicate the amino acids 
that are disordered in the Pellino2-FHA structure. The location of the RING motif is indicated 
under the sequences. The magenta diamonds mark the conserved residues in the Pellino FHA 
pT-peptide binding pockets. The black triangles mark sites of phosphorylation on Pellino1 
associated with enhanced E3 ligase activity [45]. 
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2. The Pellino FHA-like domain pT-peptide binding pocket mediates specific 
interaction with IRAK1 
Parts of this chapter were adapted from [46]. 
 
2.1. Mutations in Pellino pT peptide binding pocket disrupts Pellino association with 
IRAK1 
Various structural studies of FHA domains in complex with their cognate phosphopeptide ligands 
have elucidated how FHA domains specifically recognize their ligands. For example, the X-ray 
crystal structure of Rad53p-FHA1:Rad9p-peptide reveals that FHA-peptide binding is mediated 
by three loops at one end of the 11-stranded β-sandwich [32]. Five of the six highly conserved 
residues (G69, R70, S85, H88, and N107 in Rad53p) of the FHA domain family are located 
around the peptide-binding site. These residues make important interactions with the pT and 
peptide backbone, and maintain the structural integrity of the pT-peptide binding pocket. Alanine 
substitution of the analogous amino acids in this region of Pellino2 (such as R106 and T187/ 
N188, highlighted in Figure 2.1A) abolish interaction with phosphorylated IRAK1 (pIRAK1) [30]. 
This demonstrates that the FHA domain pT-peptide binding pocket is well conserved in Pellino2. 
Pellinos share a high degree of sequence conservation (>70% sequence identity amongst the 
human Pellinos) and all are predicted to contain the non-canonical FHA domain, which includes 
the phosphothreonine binding pocket. R104A in Pellino1 and R131A in Pellino3b (mutations 
analogous to Pellino2 R106A) also ablate pIRAK1 binding (Figure 2.1B); these results confirm 
that the pT-peptide binding site is critical for interaction of all mammalian Pellinos with pIRAK1. 
Pellino3a has previously been shown to be unable to associate with pIRAK1 in a pull-
down assay [30]. Pellino3a differs from Pellino3b only in the presence of a glutamate-rich 24 
amino acid insertion (Figure 2.1C). This insertion is predicted to lie adjacent to the FHA domain 
pT-peptide binding site (Figure 2.1A) and may occlude the binding pocket or compete for 
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substrate binding as a phosphomimetic motif. A Pellino3a variant lacking the central 7 amino 
acids of the insert (Pellino3a Δ60-67) is unable to bind pIRAK1 (Figure 2.1D), whereas a 
Pellino3a variant with alanine substituted at all 6 glutamates in the insertion (Pellino3a E54-66A) 
gains the ability to interact with pIRAK1 almost to the extent observed for Pellino3b (Figure 2.1D). 
These observations argue against simple occlusion of the pT-peptide binding site. Rather, we 
suggest that the glutamates in the Pellino3a specific insertion mimic phosphorylated residues, 
bind to the pT-peptide binding pocket, and block pIRAK1 binding. In sum, these experiments 
affirm that the Pellino pT-peptide binding pocket is critical for mediating interaction with pIRAK1.  
 
2.2. Far western analysis of Pellino2:IRAK1 interaction 
A caveat of using lysates in our pull-downs is that we cannot tell whether Pellinos are directly 
interacting with IRAK1 or whether there is a bridging protein that mediates the Pellino-IRAK1 
interaction. Furthermore, since our pull-down assays are only able to detect Xpress-tagged 
proteins that interact with Pellinos, our assays cannot distinguish whether Pellinos are able to 
discriminate between phosphothreonines on other proteins and specific phosphorylation sites on 
IRAK1. We used far western analysis to determine if Pellinos can directly target IRAK1 that has 
been transiently overexpressed in HEK293T cells. Complementary to western blotting, far 
western analysis can detect specific protein-protein interactions, but with a non-antibody probe –
in our case, Pellino2. As seen in Figure 2.2, Pellino2 specifically detects IRAK1, despite the 
presence of multiple proteins with phosphothreonines (as detected by the α-pT western blot; 
Figure 2.2, 2nd left panel). By contrast, when using Pellino2 R106A variant as a probe, there is 
no detection of IRAK1 on the far western blot (Figure 2.2, far right panel). We conclude from 
these results that Pellino2 interacts directly with IRAK1 and not with any other phosphorylated 
protein in HEK293T cells.  
 
  
15 
2.3. Pellino2 FHA domain can interact with Rad9p-derived peptide 
FHA domains can bind phosphothreonine-containing peptides, and typically show selectivity for 
phosphothreonine in a particular sequence context [47]. To determine whether the Pellino FHA-
like domain shares this property, we investigated Pellino2’s ability to bind phosphothreonine-
containing peptides. We first analyzed binding to a phosphopeptide based on amino acids 188–
196 of the Rad9 sequence (where T192 is phosphorylated). This peptide (Rad9pT192) has been 
shown to bind to Rad53-FHA1 [32,48] and EmbR-FHA [49]. As shown in Figure 2.3A, the 
Rad9pT192 peptide can also interact with Pellino2 in the context of a bead pull-down assay. The 
R106A mutation, which abolished IRAK1 binding by Pellino2, also prevents it from binding the 
Rad9pT192 peptide. Moreover, an unphosphorylated control peptide with the same sequence 
(Rad9T192) does not interact with Pellino2 –demonstrating this interaction is phosphorylation 
dependent (Figure 2.3A). Together, these data strongly suggest that the Pellino FHA core 
resembles other FHA domains in its ability to recognize phosphothreonine-containing sequences; 
furthermore, this mode of interaction is likely to contribute to recognition of phosphorylated IRAK1 
by Pellinos.  
There are no threonines in IRAK1 that are in a sequence context that resembles 
Rad9pT192. We tested binding of Pellinos to a series of phosphopeptides based on IRAK1 
phosphorylation sites that have been reported in the literature [50,51] or that are predicted by 
NetPhos 2.0 [52] (Figure 2.3B-D and summarized in Table 2.1). None of these peptides interacts 
with Pellino2 in the qualitative bead pull-down assay (Figure 2.3B). While we found that Pellino1 
and 3b can interact with the Rad9pT192 peptide, we could not detect interaction with any of the 
IRAK1-derived peptides (Figure 2.3C). In addition, the Pellino2 construct with only the FHA-like 
domain (Pellino2-FHA, residues 15-275) has the same binding preferences as full-length Pellino2 
(Figure 2.3D). This suggests that the Pellino FHA-like domain is able to discriminate between the 
Rad9pT192 peptide and these IRAK1-derived peptides; therefore, Pellinos are able to recognize 
pT in a local sequence context.  
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One limitation to our peptide pull-down assay is that peptides need to be amine coupled 
to agarose beads. Since the amine coupling efficiency is dependent on the pI of the individual 
peptide, we could not ensure that equal amounts of individual peptides were coupled to the 
agarose beads. Thus, identifying interactions with certain pT-peptides may only occur within a 
narrow detection range. For investigating the determinants of Pellino pT-peptide specificity along 
with the identification of a cognate Pellino binding motif on IRAK1, we used a quantitative 
fluorescence polarization peptide binding assay (see Chapter 3).  
 
2.4. Pellino2 can protect IRAK1 from threonine dephosphorylation 
Previous Pellino2 pull-downs of calf intestinal phosphatase (CIP)-treated IRAK1 show that the 
removal of IRAK1 phosphorylation sites disrupts Pellino2 association and therefore, this 
association is phosphorylation dependent [30]. Our peptide binding assays now suggest that not 
only is the Pellino2:IRAK1 interaction phosphorylation dependent, this interaction relies upon 
Pellino2 recognition of specific phosphorylation sites on IRAK1. Corroborating with this result, 
when we treated IRAK1 with Antarctic phosphatase (AP) in the presence of excess Pellino2, we 
find that IRAK1 is not fully dephosphorylated (indicated by the lack of the lower band of the 
doublet seen in the AP-only lane; Figure 2.4, top panel). Even in the presence of Pellino2, AP-
treatment increases the mobility of IRAK1, which suggests that there are phosphorylation sites 
that are not protected from dephosphorylation. Thus, we conclude that Pellino2 does not bind to 
all phosphorylation sites on IRAK1; rather, Pellino2 recognizes and binds to specific IRAK1 
phosphorylation sites.  
 
2.5. Mutation in the Pellino pT-peptide binding pocket disrupts IRAK1 polyubiquitination 
Pellino association with substrate is a prerequisite for the ubiquitination of substrate. Thus, we 
presumed that mutations that disrupt substrate binding should also disrupt substrate 
ubiquitination. To test this, we transiently expressed Pellino2 and IRAK1 in HEK293T and 
  
17 
detected for polyubiquitination of IRAK1. Indeed, when Pellino2 and IRAK1 are transiently co-
expressed, there is robust polyubiquitination of IRAK1 (Figure 2.5); by contrast, no 
polyubiquitination of IRAK1 is detected in the presence of the Pellino2 R106A variant. 
Interestingly, we find that when co-expressed with IRAK1, Pellino2 acquires post-translational 
modifications, as demonstrated in the mobility shift on the α-Xpress blot (Figure 2.5, lower panel). 
Since IRAK1 has been shown to phosphorylate Pellinos in vitro [13,45], we speculate that 
Pellino2 is phosphorylated by IRAK1. As expected, these modifications are also not detected on 
Pellino2 R106A.  
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Figure 2.1. The Pellino FHA domain phosphothreonine-peptide binding pocket is essential 
for interaction with IRAK1.  
(A) Cartoon representation of the Pellino2-FHA structure (PDB ID: 3ega) looking onto the face of 
the pT-peptide binding pocket. The canonical FHA domain and the FHA wing are colored in green 
and blue, respectively. Highlighted in magenta are the highly conserved residues that are crucial 
for binding to phosphorylated peptides and proteins. Dashed lines represent the location and 
length of 2 disordered loops within the FHA domain. For Pellino3a, an additional 24 amino acids 
are predicted to be inserted within disordered loop 1. (B) Substitution of alanine at a key arginine 
in the FHA domain phosphothreonine (pT) binding pocket of Pellino1, 2, and 3b ablates IRAK1 
interaction. (C) Sequence alignment of the β1-β2 region of the 4 Pellinos used in this study. The 
24-residue, glutamate-rich insert unique to Pellino3a is highlighted. The β-strands 1 and 2 from 
the Pellino2 FHA domain structure (PDB ID: 3ega) are shown above the sequences. Starting 
from the residue 30 of Pellino3a, dots above the sequences indicate every 10th amino acids. 
Dashed lines represent disordered regions of Pellino2. (D) Pellino3a and a Pellino3a variant with 
a truncation in the glutamate-rich insert (Pellino3a Δ60-67) do not interact with IRAK1. 
Substitution of alanine at every glutamate in the Pellino3a insertion confers IRAK1 binding 
property to Pellino3a. For (B) and (D), the indicated GST-fusions of Pellinos were incubated with 
HEK293T lysates that contained overexpressed Xpress-tagged IRAK1. Following washing, bound 
proteins were eluted by denaturation, analyzed by SDS-PAGE, and visualized by western 
analysis with α-Xpress to detect IRAK1, and Coomassie blue staining to detect the GST-fusion 
proteins. “In” indicates 4% of lysate. Positions of molecular mass markers are shown. 
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Figure 2.2. Far western analysis of Pellino2:IRAK1 interaction. 
HEK293T lysates containing transiently expressed FLAG-IRAK1 was separated on SDS-PAGE 
and immobilized onto nitrocellulose membranes. Western blots were probed with α-FLAG, α-pT, 
α-His. Far western (FW) blots were probed with purified His6-Pellino2 wild-type or R106A variant, 
then immunoblotted for α-His. While many bands appear on the α-pT blot, His6-Pellino2, but not 
the R106A variant, only interacts robustly with IRAK1. Triangles represent increasing amounts of 
HEK293T lysates loaded on SDS-PAGE gels.  
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Figure 2.3. Pellinos specifically interact with Rad9pT192 peptide. 
For A-D, peptides amine-coupled to agarose beads were incubated with purified Pellinos 1, 2, 
2R106A, 2-FHA, and 3b. Pellinos were then eluted by denaturation, analyzed by 12.5% SDS-PAGE 
and detected with Coomassie blue reagent. (A) Pellino2 interacts with the Rad9pT192 peptide, 
but not the unphosphorylated Rad9T192 peptide. The Pellino2 R106A variant, which does not 
interact with IRAK1 (Figure 2.1A), also does not interact with the Rad9-derived peptides. (B) 
Pellino2 does not interact with any of the IRAK1-derived peptides that were tested. (C) Like 
Pellino2, Pellinos 1 and 3b have similar binding preferences for Rad9pT192 and IRAK1-derived 
peptides. (D) Pellino2-FHA has the same peptide binding preferences as Pellino2, which 
indicates that the FHA-like domain mediates interaction with Rad9pT192 peptide. In indicates 
~1% input. FTR1 peptide is a non-phosphorylated peptide used as a negative control. The 
sequences of the peptides used are summarized in Table 2.1. 
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Table 2.1. Summary of phosphothreonine peptide pull-downs of Pellinos 
Peptide pull-downs were performed as described in Figure 2.3. “−“ indicates did not test. 
 
Peptide Peptide sequence Interacts with 
Pellino1? 
Interacts with 
Pellino2? 
Interacts with 
Pellino3b? 
IRAK1pT54 WVRDQpTELRL No No No 
IRAK1pT66 SGQRpTASVLW − No − 
IRAK1pT114 WSPGTpTAPRP No No No 
IRAK1pT152 YPGSQpTHSES − No − 
IRAK1pT209 WISRGpTHNFSE − No − 
IRAK1pT387  TVRGpTLAY − No − 
Rad9 T192 WSLEV TEADT − No − 
Rad9pT192 WSLEVpTEADT Yes Yes Yes 
FTR1 GHLPF TKNLQ No No No 
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Figure 2.4. Pellino2 can prevent complete threonine dephosphorylation of IRAK1.  
HEK293T lysates containing transiently expressed Xpress-IRAK1 were incubated with or without 
Antarctic phosphatase (AP, 5U per reaction), and with or without Pellino2 (1µM). These lysates 
were separated on SDS-PAGE and visualized by western analysis using α-Xpress and α-pT. 
IRAK1 without AP or Pellino2 runs as a 125kDa band on both western blots. When treated with 
AP, two bands with faster mobility appear on the α -Xpress immunoblot: the slower band also 
appears on the α-pT blot and is therefore partially dephosphorylated (pIRAK1*); the faster 
migrating band is absent from the anti-pT immunoblot and therefore is presumed to be completely 
dephosphorylated IRAK1. When Pellino2 is added, the faster migrating band disappears –
indicating specific threonines on IRAK1 are being protected from dephosphorylation.  
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Figure 2.5 Mutation in the Pellino pT-peptide pocket disrupts IRAK1 polyubiquitination 
Xpress-Pellino2 wild-type or R106A and Xpress-IRAK1 were either individually or co-transfected 
into HEK293T. Immunoblot analysis was performed on IRAK1 immunoprecipitated from these 
HEK293T lysates; α-ubiquitin was used to detect polyubiquitination of IRAK1 and αXpress was 
used to detect IRAK1 and co-immunoprecipitated Pellino2. Substitution of alanine at a key 
conserved amino acid in the pT-binding region of the Pellino FHA core abolishes IRAK1 
polyubiquitination in HEK293T cells. Furthermore, Pellino2 R106A has a mobility shift which 
indicates a loss of post-translational modifications.  
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3. The determinants of Pellino substrate specificity 
Parts of this chapter were adapted from [46]. 
 
3.1. Identification of an IRAK1-derived Pellino2 binding domain  
To gain additional insight into the binding determinants of Pellino2, we performed an IRAK1 
truncation analysis to identify binding regions of IRAK1 that can interact with Pellino2. IRAK1 
truncation variants (Figure 3.1A) were transiently overexpressed in HEK293T cells and tested for 
their ability to associate with GST-Pellino2 (Figure 3.1B). Deletion of the N-terminal death domain 
(IRAK1 ΔDD) significantly reduces the fraction of IRAK1 that binds to GST-Pellino2 –to the point 
where only a small proportion of the IRAK1 ΔDD input is enriched as compared to full-length 
IRAK1. Minimal interaction above background is observed for a truncation that also lacks the C-
terminal domain (IRAK1 KDL) and for the kinase domain alone (IRAK1 KD). The trend in GST-
Pellino2 pull-down of these 3 kinase domain-containing IRAK1 fragments is mirrored in the level 
of phosphorylation of each truncation, as assessed by anti-pT immunoblots (Figure 3.1B, middle 
panel). 
A fragment containing only the first 197 amino acids of IRAK1 (IRAK1-197) robustly 
associates with Pellino2 in a phosphorylation dependent manner. At least three species of 
IRAK1-197 are observed on SDS-PAGE. Only the slowest migrating species contains significant 
phosphothreonine and is highly enriched in the GST-Pellino2 pull-down fraction (Figure 3.1B). 
Enzymatic dephosphorylation of IRAK1-197 results in undetectable levels of pT in this protein and 
abolishes interaction with GST-Pellino2 (Figure 3.1C). In addition, the Pellino2 pT-peptide binding 
site variant R106A does not interact with IRAK1-197 (Figure 3.1C). IRAK1-197 lacks the kinase 
domain and must be phosphorylated by kinases endogenous to HEK293T cells. We presume that 
the same endogenous kinases that are able to phosphorylate the kinase-dead IRAK1 variant 
(IRAK1 K239A) in IRAK1-null HEK293 cells (I1a cells) [53] can phosphorylate IRAK1-197. Finally, 
a truncation variant that lacks the proline/serine/threonine-rich (PST) domain and comprises only 
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the IRAK1 death domain (IRAK1 DD) is not phosphorylated in HEK293T cells and shows 
dramatically reduced binding to Pellino2 (Figure 3.1B). This suggests that the Pellino2 binding 
region may lie within the PST domain, or that this domain is required for appropriate 
phosphorylation of IRAK1-197. 
Next, we sought to identify which threonine(s) in IRAK1-197 are important for interaction 
with Pellino2. There are 9 threonines in IRAK1-197: 5 are in the presumed unstructured PST 
domain and 4 in the death domain. Based on a structure-based sequence alignment with the 
IRAK2 death domain (PDB ID: 3mop) [54], only 3 of the 4 threonines in the IRAK1 death domain 
are predicted to be surface-exposed. We individually mutated to alanine each of these 8 
presumed surface-exposed threonines and tested each IRAK1-197 variant for interaction with 
GST-Pellino2 (Figure 3.2A, B). Alanine substitutions at T54 and T141 significantly disrupt Pellino2 
interaction (Figure 3.2B). In both cases, the IRAK1-197 variants show significantly reduced 
phosphorylation (Figure 3.2B middle panel). The phosphorylated fraction of IRAK1-197 T54A 
associates with Pellino2, whereas no phosphorylated IRAK1-197 T141A is pulled-down with 
Pellino2. This suggests that T54 in the death domain is important for phosphorylation of IRAK1-
197 –perhaps through a change in structure or oligomerization. On the other hand, T141 in the 
PST domain is likely to represent a phosphorylation site directly recognized by Pellino2.  
 
3.2. Pellino pT-peptide +3 motif preferences  
3.2.1. Pellino2 can specifically recognize IRAK1T141-derived pT-peptide 
Binding studies using synthetic phosphorylated peptides have been widely used to establish the 
specificity of many FHA domains [32,35,49,55,56]. To explore the specificity of Pellino2, we 
chose to test binding using the more stable Pellino2 truncation variant (Pellino2-FHA, residues 
15-275) with fluorescently labeled phosphopeptides in a fluorescence polarization assay. A 
peptide comprising amino acids 137-145 of IRAK1 with a phosphothreonine at position 141 
(pT141) binds to the Pellino2-FHA with a KD value of 0.82 µM (Figure 3.2C and Table 3.1). The 
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affinity for a scrambled version of pT141 is more than 100-fold weaker, and no binding is detected 
for the non-phosphorylated version of this peptide. These data demonstrate that high affinity 
binding to Pellino2 relies not only on a phosphorylated threonine, but also on the local sequence 
context around this moiety. In agreement with our IRAK1-197 mutational analysis, 
phosphothreonine-containing peptides derived from the sequences around IRAK1 T54 and T152 
(pT54 and pT152) show markedly weaker affinities for the Pellino2 FHA domain than pT141 
(Figure 3.2C and Table 3.1). To validate our fluorescence polarization peptide binding assay, we 
used isothermal titration calorimetry to measure the affinity of the Pellino2-FHA for the pT141 
peptide (Figure 3.2D). We obtained a KD value of 2.9 µM, which is reasonable when considering 
the differences in experimental setup and lack of multiple independent ITC experiments due to 
limited peptide quantities. These results further support the argument that the local sequence 
context around the pT is important for optimal Pellino2 binding. In addition, our studies identify the 
region around T141 in IRAK1 as a specific high-affinity Pellino2 recognition motif.  
 
3.2.2. Pellino isoforms have different pT-peptide specificities  
The major determinant of pT-peptide recognition for many FHA domains is the amino acid located 
3 positions C-terminal to the phosphorylated threonine (+3 position) [32]. Peptide library screens 
performed on a diverse selection of FHA domains have identified four FHA pT-recognition motifs 
with different amino acids at the +3 position: pTxxD, pTxxI/L, pTxxY/M, and pTxxS/A [32]. The 
motif around T141 in IRAK1 falls in the last of these 4 groups with a serine at the +3 position. 
Henceforth, the peptide based on this IRAK1 sequence is referred to as pT141+3S. To determine 
whether pTxxS is the optimal Pellino2 pT-recognition motif, we analyzed binding of peptides with 
aspartate, isoleucine and tyrosine in place of serine at the +3 position (pT141+3D, pT141+3I and 
pT141+3Y, respectively) to Pellino2-FHA (Figure 3.3, Table 3.2). Pellino2-FHA binds most tightly 
to pT141+3Y with a KD value 4.6 fold stronger than for pT141+3S. Aspartic acid at the +3 position 
is the most unfavorable binding motif with a 5-fold higher KD value compared to pT141+3S, 
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whereas isoleucine at the +3 position shows a 2.6-fold higher KD value compared to pT141+3S. 
These data indicate that Pellino2-FHA prefers the pTxxY binding motif 4.6-, 12-, and 23-fold 
compared to the pTxxS, pTxxI and pTxxD motifs, respectively (Table 3.2, Figure 3.3B). 
We next asked whether the observed Pellino2 peptide binding preference is also seen for 
the other Pellinos. We measured binding to the same panel of fluorescently labeled peptides 
using Pellino1, 3a, and 3b truncations that contain only the FHA domain (amino acids 2-287, 40-
305 and 2-304, respectively) (data summarized in Figure 3.3 and Table 3.2). All Pellinos bind to 
the original IRAK1 derived pT141+3S, which suggests that phosphorylation of T141 plays a role 
in association of IRAK1 with all of the Pellinos (Table 3.2). Pellino3a shows the weakest binding 
to pT141+3S (KD value of 9.8 µM), which is consistent with the lack of detectable binding 
between GST-Pellino3a and pIRAK1 (Figure 2.1D).  
All Pellinos bind most tightly to the pT141+3Y peptide, and substantially disfavor binding 
to the pT141+3D motif (Table 3.2). However, differences arise in the extent to which each Pellino 
favors the pTxxY motif over the pTxxI and pTxxS motifs. As described above, Pellino2 clearly 
discriminated between all three, with the trend in KD values of pTxxY < pTxxS < pTxxI.  By 
contrast, Pellino1 shows minimal discrimination in binding between the peptides with tyrosine, 
serine and isoleucine at the +3 position (KD values of 0.77, 1.7 and 1.8 µM, respectively). 
Pellino3a and 3b, which differ only by the 24 amino acids insertion (Figure 2.1C), have very 
similar +3 motif preferences; although, the affinity in each case is ~2 fold weaker for Pellino3a 
compared to Pellino3b. Like Pellino1, the Pellino3 isoforms do not discriminate between serine 
and isoleucine at the +3 position. Yet unlike Pellino1, the Pellino3 isoforms do show more 
preference for tyrosine at the +3 position. The observed binding preferences revealed from this 
panel of pT-peptides suggest that each Pellino will have a distinct set of preferred substrates. 
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3.3. Pellinos have distinct specificities for RIP1 and TRAF6  
Knockout studies in mice indicate that Pellino1 and Pellino3 have non-redundant functions in TLR 
signaling. These divergent functions have been attributed to differential polyubiquitination of RIP1 
and TRAF6 by Pellino1 and 3, respectively [17,21]. Based on our observation that each Pellino 
has a different peptide binding profile, we postulated that Pellino1 selectively targets RIP1 over 
TRAF6, whereas Pellino3 is selective for TRAF6. We tested this hypothesis by examining the 
interaction of GST-Pellinos with these proteins transiently expressed in HEK293T cells. Much like 
IRAK1 (Figure 2.1 and 3.4A), we find that RIP1 interacts with GST-Pellino1, 2 and 3b, but not 
with GST-Pellino3a (Figure 3.4B). By contrast, TRAF6 does not interact with Pellino1 in this 
assay, whereas TRAF6 interaction is observed for Pellino2 and both isoforms of Pellino3 (Figure 
3.4C). Since substrate binding is a prerequisite for substrate ubiquitination, this binding selectivity 
of Pellinos is likely responsible, at least in part, for their different cellular functions.  
 
3.4. Distribution of FHA binding motifs in Pellino substrates 
We next asked whether it is possible to rationalize the Pellino specificity differences observed in 
our simple GST-pull-down assay by using our peptide binding results and the distribution of pT+3 
motifs in Pellino substrates (Tables 3.3 and 3.4) without any consideration of the in vivo 
phosphorylation state of these motifs. Pellino1 binds robustly to IRAK1 and RIP1 but not to 
TRAF6; this correlates with a requirement for pTxxY or pTxxS binding motifs, which are found in 
IRAK1 and RIP1, but not in TRAF6. These motifs are also found in cRel, another known Pellino1 
substrate [25]. Pellino2 interacts more robustly with IRAK1 than with RIP1 and TRAF6; this may 
reflect the strong preference of Pellino2 for pTxxY motif (Figure 3.3B), which is more frequent in 
IRAK1 than in the other two substrates. It is hard to rationalize the binding of Pellino3a to TRAF6 
and not to IRAK1 and RIP1 based on these very simple considerations. The only striking 
difference in the pT+3 motifs in TRAF6 is the representation of pTxxD, however the peptide 
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binding experiments do not suggest that Pellino3a shows any less discrimination against this 
motif than the other Pellinos.   
 
3.5. Attempts to determine high resolution Pellino:phosphopeptide structure 
To gain insight into the molecular basis of the different Pellino binding specificities, we sought to 
determine a high-resolution structure of a Pellino FHA-like domain in complex with a pT-peptide. 
Attempts to co-crystallize various constructs of Pellino1 and 2 with pT-peptides are summarized 
in Table 3.5 and Figure 3.5. In addition, pT-peptides were soaked into Pellino2-FHA crystals (see 
Chapter 6 for details), but crystals would immediately dissolve. Crosslinking Pellino2 crystals 
before pT141+3Y peptide soaks prevented crystals from dissolving, so data sets were collected 
on these crystals. Structures were solved by molecular replacement (MR) using PHASER [57] 
(see Chapter 6). There was no evidence for the peptide in the electron density maps generated 
with the MR phases. This is not surprising considering there are crystal contacts near the pT-
peptide binding pocket that are likely impinged upon the presence of peptide (Figure 3.6). 
 
3.6. Towards a Pellino3a-FHA structure 
Since the Pellino3a glutamate-rich insertion most likely acts as a phosphomimetic peptide and 
occludes the FHA domain pT-peptide binding pocket, we speculated that the Pellino3a FHA-like 
domain structure could provide clues about pT-peptide recognition. We found that the Pellino3a-
FHA construct (aa 40-305) could spontaneously crystallize (Figure 3.7A). After exhaustive 
screening for different crystallization conditions, we found that Pellino3a-FHA crystallized in 
conditions of 5-20% PEGs (400-20000 MWCO), ethylene glycol, or glycerol at very low ionic 
strengths and around neutral pH (Figure 3.7B for some examples). Many attempts were made to 
optimize these crystals (summarized in Table 3.6, and described in detail in Chapter 6) and 
improve X-ray diffraction (Figure 3.7C, D), but the best diffracting crystals were the ones originally 
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discovered to have formed spontaneously. We collected a 4.6Å data set on these Pellino3a-FHA 
crystals, but were not able to obtain a molecular replacement solution. Data collection statistics of 
Pellino3a-FHA crystals are summarized in Table 3.7.   
 
3.7. Homology modeling of Pellinos 
The peptide and substrate binding differences among the Pellinos are hard to reconcile due to 
their high degree of sequence identity and cannot be readily explained by the Pellino2 FHA 
domain crystal structure alone. Thus, we sought to perform structure-based homology modeling 
of the different Pellinos using SWISS-MODEL [58]. Although the residues that connect β4 and β5 
strands (aa120-129) appear to be disordered in the crystal structure of the Pellino2 FHA domain, 
these residues form a short α-helix in the Pellino2 homology model (Figure 3.8A, D). Like 
Pellino2, the analogous residues in Pellino1 are also modeled to be a short α-helix (Figure 3.8C). 
However, in Pellino3a and 3b, the analogous residues are modeled to be predominantly 
unstructured, but with a significantly smaller α-helix compared to Pellino1 and 2 (Figure 3.8E). 
Interestingly, these 10 amino acids share low sequence identity (Figure 3.8B) near and are 
proximal to the FHA domain pT-peptide binding pocket (Figure 3.8A). The subtle structural 
differences predicted in these Pellino homology models may provide an explanation for the 
distinct phosphopeptide preferences and substrate specificities amongst the Pellinos.  
 
3.8. Pellino substrate recognition may require more than pT-peptide recognition 
The following experimental results suggest that Pellino substrate recognition may involve more 
than a short pT-peptide sequence.  
3.8.1. Pellino2 interacts with IRAK1 mutants T54A and T141A 
Despite the fact that the T54A and T141A mutations in IRAK1-197 abolish interaction with 
Pellino2, we found that these mutations in the context of full-length IRAK1 have no effect on 
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Pellino binding (Figure 3.9). This suggests that there are additional Pellino binding sites on IRAK1 
that are not present on IRAK1-197. These additional binding sites could be other phosphorylation 
sites, as there are several threonines within 198-712 that have pTxxS/A and pTxxY motifs. In 
addition to multiple phosphorylation sites that Pellinos may recognize, it is possible that IRAK1 
may contain non-phosphorylated determinants that enhance Pellino interaction; this could be an 
extension to the short peptide sequence surrounding the pT site, or additional binding sites 
(which may include secondary structure elements) more distal to the pT site. This has been 
demonstrated for the FHA-domain containing Myobacterium tuberculosis FhaA, which prefers its 
cognate binding partner MivN over a library screen-optimized peptide due to an additional binding 
surface on a helix of MivN that make contacts with the FHA domain [59].  
3.8.2. Pellino2 R224A disrupts interaction with IRAK1, but not pT-peptide 
While the conserved amino acids in the FHA domain are responsible for mediating interaction 
with ligands and maintaining the structural integrity of the pT-peptide binding pocket, non-
conserved amino acids in the interacting loops mediate sequence specificity for the pT+3 residue  
[55,56,60,61]. FHA domain structural studies also indicate that insertions between the β-strand 
connecting loops may attribute to the functional diversity of FHA domains [34]. The wing of the 
Pellino FHA-like domain is a very striking example of such insertions. Canonical FHA domains 
show more subtle variations such as an eight-residue helical insertion within the β4/β5 loop of the 
human Rad53 homolog, CHK2 (check point kinase 2) FHA domain [33]. Based on the highly 
unusual insertions in the Pellino FHA domain, we speculated that the non-canonical features of 
the Pellino FHA-like domain (highlighted in Figure 3.10A-B) make additional contacts that 
mediate substrate recognition.  
We performed a structure-based mutational analysis of conserved surface residues of the 
Pellino2 β9/β10 loop and the unusual wing appendage that are on the same face of the pT-
peptide binding pocket (Figure 3.10B). None of the mutations in the wing appendage (Q66L, 
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K69A, R85A, N165A) disrupted interaction with IRAK1 (Figure 3.10C). However, a substitution of 
alanine at R224 of the Pellino2 β9/β10 loop disrupts interaction with IRAK1 (Figure 3.10C). This 
mutation does not affect binding to pT-peptides (Figure 3.10D), confirming that loss of IRAK1 
interaction is not due to the disruption of the structure of Pellino FHA R224A variant. This further 
supports the idea that Pellino substrate recognition may require protein-protein interactions 
additional to pT-peptide binding. 
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Figure 3.1. Pellino2 interacts with IRAK1-197 in a phosphorylation dependent manner.  
(A) Schematic representations of IRAK1 and truncation variants indicating the amino acids of full 
length (FL) IRAK1 that are included in each variant generated. DD: Death domain; PST: 
proline/serine/threonine-rich domain; KD: kinase domain, Ct: C-terminal domain. (B) GST-
Pellino2 pull down analysis of the indicated IRAK1 variants expressed in HEK-293T cells, 
essentially as described for Figure 1B. For each IRAK1 variant, three samples were analyzed: 4% 
of the HEK293 cell lysate (In), plus samples from GST alone and GST-Pellino2 pull-downs. Total 
Xpress-tagged protein was detected with α-Xpress antibody (upper panels). Western blots were 
probed with anti-phosphothreonine (α-pT) antibody (middle panel). Lower panel shows 
Coomassie stain to verify equal loading of GST and GST-Pellino2. IRAK1 (FL) and IRAK1-197 
show robust interaction with Pellino2. IRAK1-197 migrates as several discrete bands, the range 
of which is indicated by a vertical line. The faster migrating species are not observed on the α-pT 
blot and presumed to represent unphosphorylated IRAK1-197. Expected positions of each IRAK1 
variant is shown, as are positions of molecular weight markers. For clarity, the position of IRAK1 
KD is indicated with a < on the left blots, since this species runs at the same position as the 
phosphorylated IRAK1-197. A * after the protein name indicates that this specie is detected on 
the α-pT blot. Non-specific interaction of α-pT with GST-Pellino2 partially obscures the IRAK1 
∆DD on this blot. (C) Pellino2-IRAK1-197 interaction is ablated when IRAK1-197 is treated with 
calf intestinal phosphatase (CIP) or when Pellino2 FHA domain pT-peptide binding pocket 
contains an alanine substitution at a key arginine (Pellino2 R106A). GST-pull downs were 
performed as for part B.  
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Figure 3.2. Pellino2 specifically interacts with a peptide motif around pT141 of IRAK1-197.  
(A-B) GST-Pellino2 was used to pull down Xpress-IRAK1-197 variants with alanine substituted at 
8 different threonines. Only T54A and T141A show reduced interaction with Pellino2. (B) T54A 
and T141A also show reduced threonine phosphorylation. T152A is a representative example of 
variant that interacts with Pellino2 to the same extent as wild type IRAK1-197. Blots were 
generated as described in the legends to Figures 2.1 and 3.1. For A-B, a * after the protein name 
indicates that this specie is detected on the α-pT blot. (C) Binding of the indicated fluorescein-
labeled peptides to increasing concentrations of Pellino2-FHA (Pellino2 15-275) as monitored by 
fluorescence polarization. A representative data is shown for each peptide. The curves indicate 
the fit to a simple binding isotherm for each data set shown. KD values for at least three 
independent experiments are summarized in Table 3.1. (D) Binding of Pellino2-FHA to pT141+3S 
peptide using isothermal titration calorimetry (ITC). The top section shows the raw calorimetric 
data for the bottom section shows the integrated heat changes, corrected for heat of dilution, and 
fitted to a single-site binding model. 
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Table 3.1. Binding affinity of IRAK1-derived peptides to Pellino2-FHA domain. 
The KD values for binding of Pellino2-FHA to the indicated peptides were determined from at least 
three independent fluorescence polarization assays (Figure 3.2C). Baseline corrected data were 
fit to a simple binding equation. NB indicates no binding detected. All peptides include an N-
terminal tyrosine to allow for spectroscopic quantification. 
 
Peptide Sequence KD (µM) 
IRAK1T141 S-S-A-S- T-F-L-S-P NB 
IRAK1pT141 S-A-S-S-pT-F-L-S-P 0.82 ± 0.35 
IRAK1pT141 scrambled P-A-S-F-pT-S-S-L-S > 50 
IRAK1pT54 V-R-D-Q-pT-E-L-R-L 12.6 ± 1.8 
IRAK1pT152 P-G-S-Q-pT-H-S-G-P > 50 
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Figure 3.3. Pellinos have different phosphothreonine peptide binding specificities.  
(A) The fold change in the KD value for the binding of each Pellino to IRAKpT141 and derivative 
peptides relative to the binding of that Pellino to the pT141+3Y peptide (+3Y). Each Pellino binds 
the +3Y peptide with the highest affinity (Table 3.2), which is normalized to 1 as indicated by the 
dashed line. Fold change in KD values for binding to the pT141+3D (+3D, white bars), pT141+3I 
(+3I, red bars) and pT141+3S (+3S, blue bars) are shown. (B) Fluorescence polarization binding 
assay for each Pellino with the pT141+3Y peptide, exactly as for Figure 3B. A representative data 
set is shown for the FHA domain of Pellino1 (red), Pellino2 (green), Pellino3a (black) and 
Pellino3b (blue). Curves indicate the fit to a simple binding isotherm for each data set shown. KD 
values for at least three independent experiments are summarized in Table 3.2. 
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Figure 3.4. Pellinos have different specificities for TRAF6 and RIP1.  
GST-Pellino pull-downs of (A) Xpress-IRAK1 and (B) Xpress-RIP1 show that only Pellino3a 
cannot interact with IRAK1 and RIP1. (C) GST-Pellino pull-downs of Xpress-TRAF6 show that 
only Pellino1 cannot associate with TRAF6. This demonstrates that Pellinos have different 
substrate specificities. All pull-downs were performed as described in Figure 2.1. 
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Table 3.3. Frequency of FHA binding motifs in Pellino substrates. 
The number of times each motif appears in these Pellino substrates is indicated. Where there are 
two possible amino acids in the +3 position in the FHA motif, the occurrence of the amino acid 
analyzed in this study (I, S, Y) is listed first, followed by the occurrence of the second amino acid. 
  
    pTxxD pTxxI / L pTxxS /A pTxxY /M 
IRAK1 − − / 3 1 / 5 2 / − 
RIP1 − − / 4 5 / − 1 / 2 
TRAF6 4 2 / 2 − / − − / 2 
RIP2 − 2 / 3 4 / − 2 / 1 
cRel 3 − / 5 6 / − 1 / 1 
42 
 
Table 3.4. FHA domain binding motifs in Pellino substrates 
The FHA domain binding motifs of IRAK1, RIP1, TRAF6, RIP2, and cRel are listed. Positions 
refer to the amino acid number of the threonine shown in large, bold font. The amino acids in the 
+3 position in the sequence is colored according to the binding motif (pTxxD, pTxxI/L, pTxxS/A 
and pTxxY/M). The +3 amino acids that were investigated in this study - D, I, S and Y - are 
colored in purple, green, red, and blue, respectively. The +3 amino acids that were not 
investigated in this study - L, A and M - are indicated in pale green, pink and light blue 
respectively. 
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Figure 3.5. Pellino1:pT141+3S peptide quasi crystals 
Equal volumes of full-length Pellino1 and pT141+3S peptide (1:1 molar ratio, 10mg/ml total in 
10mM HEPES pH 7, 80mM NaCl, 1mM DTT) and reservoir solution (50mM Imidazole pH 7, 5% 
PEG 3350, 100mM CaCl2) were mixed and equilibrated over the reservoir solution at 20°C. Quasi 
crystals would grow up to ~10-15µm in size and would also appear without peptide. Clusters of 
crystals are ~30µm2 in the pictured dimension. 
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Figure 3.6. The FHA domain pT-peptide binding site of Pellino2 crystal is a crowded 
environment.  
Close up view of the pT-peptide binding pockets of Rad53-FHA1 domain (gray, PDB ID: 1gxc) 
superimposed onto the Pellino2-FHA domain (green, PDB ID: 3ega). Arginine 106 of Pellino2-
FHA domain is highlighted in magenta. Highlighted in orange is the Rad9p peptide bound to 
Rad53-FHA1. The Rad9p peptide clashes with the Pellino2-FHA domain symmetry mate (cyan), 
suggesting that the crowded environment may not be able to accommodate pT-peptide.  
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Figure 3.7. Crystallization of Pellino3a-FHA 
(A) Pellino3a-FHA (residues 40-305) crystals that formed in 10mM HEPES pH 7, 150mM NaCl, 
5mM βME. The left panel shows crystals that spontaneously formed during a 6-week incubation 
period at 4°C in a 1.5ml microcentrifuge tube. The right panel shows optimized Pellino3a-FHA 
crystals formed by hanging drop vapor diffusion. See Table 3.7 for data collection statistics on a 
data set from a Pellino3a-FHA crystal that formed spontaneously. (B) Other conditions that yield 
Pellino3a-FHA crystals: 75mM HEPES pH 7, 600mM sodium tartrate (left panel); 0.1M MES pH 
6.5, 6% (w/v) PEG 20,000 (middle panel); 100mM HEPES pH 7.5, 2M ammonium formate (right 
panel). (C) Dehydration of Pellino3a-FHA crystals improves X-ray diffraction quality. Pellino3a-
FHA crystals were transferred to 1-2µl drops containing 10mM HEPES pH 7, 150mM NaCl, and 
5mM βME with or without 10-15% ethylene glycol. The drops were equilibrated with the same 
solution in the reservoir for ~16 hours at 20°C. 66% ethylene glycol, 10mM HEPES pH 7, 150mM 
NaCl, and 5mM βME was slowly added to the drops until the concentration of ethylene glycol was 
~33%. Crystals were flash frozen directly from the drop. Diffraction data was collected at the 
UPenn X-ray home source. (D) Seeding Pellino3a-FHA crystals also improved crystal formation. 
A 1:1000 dilution of crushed Pellino3a-FHA crystals was streak seeded into Pellino3a (2.8-
8.5mg/ml) and reservoir solution (75mM HEPES 7, 600mM sodium tartrate) mixed in equal 
volumes and equilibrated over reservoir solution at 20°C. 
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Table 3.6. Summary of optimized Pellino3a crystallization conditions  
Pellino32-FHA crystals grew to 100-400µm3.  Pellino3a-FHA (6-10mg/ml) was crystallized in 
these conditions. 
 
Condition Buffer pH Precipitant Salt/Additive 
1 10mM HEPES 7 150mM NaCl 5mM βME 
2 75mM HEPES 7 600mM NaTartrate  
3 100mM MES 6.5 3% PEG 3350  
4 100mM MES 6.5 2.5% PEG 8,000  
5 100mM NaPhosphate 6.5 5% PEG 8,000  
6 100mM NaPhosphate 7 3-5% PEG 5,000  
7 100mM HEPES 7 6% PEG 10,000 37.5mM MgCl2 
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Table 3.7. Data collection statistics for Pellino2:pT141 peptide and Pellino3a-FHA 
Numbers in parentheses refer to the last resolution shell. Rsym = Σ|Ih-<Ih>|/Σlh, where Ih= average 
intensity over symmetry equivalent measurements. 
 
 Pellino2:pT141 peptide Pellino3a-FHA 
Space group F222 I213 
Cell dimensions a=84.4, b= 86.7, c = 
163.6  
a, b, c = 170.0Å 
X-ray source APS 23-ID-B APS 23-ID-B 
Wavelength (Å) 1.0332 1.0331 
Resolution limit (Å) 2.05 5.2 
Measured/Unique 130244 / 17956 109705 / 3231 
Fold redundancy 3.3 (3.2) 6.2 (6.3) 
Completeness (%) 97.4 (98.8) 99.2 (100) 
Rsym (%) 5.4 (61.0) 7.7 (44.5)  
<I/σ> 22.6 (2.7) 25.8 (4.9) 
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Figure 3.8. The Pellino β4/β5 loop may confer Pellino substrate specificity 
(A) Cartoon representations of superimposed homology models of Pellino1, 2 and 3b. Pellino3a 
and Pellino3b are essentially modeled the same except for the 24 amino acid insertion. We 
therefore did not include the Pellino3a homology model to avoid redundancy. The β1/β2 loops in 
Pellinos 1, 2, and 3b are modeled to be very similar in structure and was removed for a better 
view of the FHA domain pT-peptide binding pocket. (B) Sequence alignment of the residues in 
β4/β5 loop of Pellino1, 2, 3a and 3b. The secondary structure elements of the Pellino2-FHA core 
(PDB ID: 3ega) are shown above the sequence alignment; the dotted line represents residues 
that are disordered in the structure. Residues are colored by percent sequence identity (darkest 
blue represents the greatest sequence identity). (C-E) Close up views of the Pellino FHA domain 
pT-peptide binding pocket and the modeled β4/β4 loop of Pellino1 (C), Pellino2 (D), and Pellino 
3b (E). R104, R106, and R131 of Pellino 1, 2, and 3b, respectively, are highlighted in magenta. 
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Figure 3.9. Pellino2 still interacts with IRAK1 T54A and T141A mutants 
Pull-downs of IRAK1 and IRAK1 variants from HEK293T cells with immobilized GST-Pellino2. 
Experiments were performed exactly as described in Figure 3.1. T54A and T141A mutations do 
not disrupt IRAK1-Pellino2 association. 
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Figure 3.10. Pellino2 R224A disrupts interaction with IRAK1, but not Rad9pT192 peptide. 
(A) A topology diagram of the Pellino2 substrate binding domain structure highlights the non-
canonical features of the Pellino FHA-like domain: the Pellino wing (in blue) and the β9/β10 loop 
within the FHA core. For comparison, the position of the β9-strand in canonical FHA domains is 
shown in gray. (B) Cartoon representation of the Pellino2 FHA core pT-peptide interaction 
surface. Conserved residues that are part of the FHA core pT-peptide binding pocket are 
highlighted in magenta. Residues that were mutated in (C) are highlighted in orange. (C) Pull-
downs of IRAK1 from HEK293T cells with immobilized GST-Pellino2 and Pellino2 mutants. Both 
R224A and R106A mutations disrupt interaction with IRAK1. (D) Rad9pT192 peptide pull-downs 
of GST-Pellino2 and Pellino2 variants. Unlike Pellino2 R106A, Pellino2 R224A can still interact 
with the Rad9pT192 peptide. (A) was adapted from [30]. 
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4. Discussion of Chapters 2 and 3 
Parts of this chapter were adapted from [46]. 
 
4.1. pT-peptide binding of Pellinos 
When comparing peptide binding affinities between the Pellinos, Pellino2 interacts most tightly 
with all 4 pT141 peptide variants (Table 3.2). This may reflect the fact that we have focused most 
of our efforts to elucidate the molecular basis of Pellino2-IRAK1 interaction. However, if this high-
affinity binding is an intrinsic property of Pellino2 compared to the other members of this family of 
E3 ligases, this may explain the difficulty in identifying the true physiologically relevant Pellino2 
substrates based on experiments using overexpression or incomplete knockdown of this protein. 
Alternatively, high affinity binding may be a property of all Pellino FHA domains, but we have not 
identified the optimal binding motif for Pellino1, 3a and 3b in this study.  
Our mutational analysis of Pellino3a suggests that its unique insertion attributes to 
substrate specificity and therefore should affect pT-peptide binding as well. Indeed, our pT-
peptide binding experiments show that compared to all the Pellinos, Pellino3a binds the weakest 
to the pT141 peptide variants. However, the fact that Pellino3a is able to interact with these 
peptides only 2-fold weaker than Pellino3b suggests that the Pellino3a unique insertion only binds 
very weakly with the Pellino3a FHA domain pT-peptide binding pocket. Future studies should 
determine the binding affinity of Pellino3b for a peptide derived from the Pellino3a insertion. 
Moreover, it would be interesting to see if Pellino3b is still able to interact with IRAK1 in the 
presence of the same peptide. 
 
4.2. Identifying more specific Pellino binding sites 
To our knowledge, this is the first identification of a specific Pellino2 binding site on one of its 
physiologically relevant substrates. Here, we provide some ideas on how to characterize more 
Pellino binding motifs.  
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Despite the fact that we assayed a very limited set of peptides, our study has found a pT-
peptide, pT141+3Y peptide, that can interact with Pellino2 with a KD of 180nM (Table 3.2). This is 
quite impressive considering the highest affinity known for an FHA domain-pT peptide interaction 
is for the Rv0020c FHA domain with its peptide library screen-derived peptide that has a KD of 
~100nM [35]. Thus, our study’s approach of dissecting the Pellino-IRAK1 interaction may also 
successfully elucidate the specific sites on other substrates that Pellinos target.  
Consideration of the physiologically relevant phosphorylation state of Pellino substrates 
will also assist in identifying more Pellino binding motifs. In our studies, phosphorylation of Pellino 
substrates is entirely dependent on substrate overexpression, which is presumed to stimulate 
substrate phosphorylation by autophosphorylation or an endogenous kinase. A more refined 
approach would be to look for Pellino interaction with substrates that become phosphorylated 
upon appropriate stimulation of immune receptors. Examining the substrate specificity of kinases 
that are responsible for phosphorylating Pellino substrates may additionally provide clues to 
physiologically relevant phosphorylation sites on Pellino substrates. 
An extension of the dephosphorylation protection assay we performed on IRAK1 can also 
help to identify other phosphorylation sites on IRAK1 and other Pellino substrates. Mass 
spectrometry-based analyses of phosphatase-treated substrates in the presence Pellinos can 
elucidate the phosphorylation sites that are protected by Pellinos. In addition, comparing the 
dephosphorylation protection profiles of all 4 Pellinos can hypothetically uncover more specificity 
differences amongst the Pellinos.  
Interestingly, the TxxY sequence is found in the activation loops of IRAK1 (T387), RIP1 
(T189), and RIP2 (also at T189). Kinase activation frequently involves the phosphorylation of 
specific residues within the activation loop [62] so these threonines are most likely 
phosphorylated in vivo; in fact, Thr387 of the IRAK1 activation loop is an autophosphorylation or 
IRAK4 phosphorylation site crucial for the activation of IRAK1 kinase activity [50,63]. The 
common occurrence of TxxY in these kinase activation loops suggests that the Pellinos may 
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target these sites. Mutational analyses of the RIP1, RIP2 and IRAK1 kinase activation loops may 
be too disruptive to test whether Pellinos bind to these regions. In fact, alanine substitution of 
IRAK1 T387 disrupts kinase activity [50]. While we were not able to detect IRAK1pT387-derived 
peptide (pT387 peptide) interaction with Pellino2 in our qualitative peptide pull-down assay 
(Figure 2.3), we have not had the opportunity to measure Pellino2 binding to pT387 peptide using 
a quantitative assay due to limited peptide quantities. Future studies should measure Pellino 
binding to peptides derived from the kinase activation loops of Pellino substrates.  
 
4.3. Phosphorylation-dependent regulation of Pellino specificity and substrate recognition  
4.3.1. Substrate phosphorylation may disrupt Pellino binding 
Based on our peptide binding analysis, all 4 Pellinos show the weakest binding to the 
IRAK1pT141-derived peptide variant containing the pTxxD motif –in each case at least 13 times 
weaker than for the pT141+3Y peptide (Table 2 and Figure 4A). This trend against aspartate (a 
phosphomimetic residue) at the +3 position could reflect negative selection of binding sites with a 
phosphorylated residue in this position. Phosphorylation of a pTxxS motif would be expected to 
reduce Pellino binding and could represent a regulatory mechanism of Pellino substrate 
recognition.  
There is evidence to suggest that this form of regulation may occur at the IRAK1pT141 
site that we found to be a specific Pellino2 target. Upon stimulation of THP-1 cells with R-848 (a 
TLR7/8 ligand), IRAK1 is known to become phosphorylated at a number of specific serines and 
threonines in the PST domain around T141 [64]. Interestingly, the same IRAK1 PST region is the 
target of two other IRAK1 binding partners involved in TLR signaling, the prolyl isomerase Pin1 
and the substrate recognition domain of the SCF-β-TrCp E3 ubiquitin ligase (β-TrCp) [64,65]. In 
fact, Pin1 and β-TrCp require phosphorylation of serines adjacent to T141 (including S144 at the 
+3 position) for association with IRAK1. Our pT peptide binding analysis suggests that 
phosphorylation of these adjacent serines would disfavor Pellino binding. Thus, the IRAK1 
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phosphorylation state may dictate which post-translational modifiers can associate with IRAK1 
and hence, influence the regulation of downstream TLR signaling events. It would be interesting 
to investigate whether these IRAK1-binding proteins are activated under the same TLR-
stimulation conditions and if so, determine an order in which these proteins associate with IRAK1. 
Moreover, future studies should look at whether Pellinos compete with Pin1 and β-TrCp for 
IRAK1 association.  
4.3.2. Phosphorylation may affect Pellino specificity 
Pellino phosphorylation has previously been shown to enhance the catalytic activity of Pellinos in 
vitro [13,45], however it remains unclear whether phosphorylation also affects Pellino substrate 
specificity. Phosphorylation of the E3 ubiquitin ligase Nedd4-2 inhibits substrate binding and is a 
regulatory mechanism to maintain proper epithelial Na+ transport [66]. In a similar manner, 
phosphorylation of Pellinos may also modulate substrate specificity. In our study, we found that 
Pellino3a contains a phosphomimetic insert that prevents IRAK1 association. We speculate that 
other Pellinos can be phosphorylated in a manner that mirrors auto-inhibition of Pellino3a 
substrate binding. One potential site is the disordered serine/threonine-rich β4/β5 loop, which 
homology modeling suggests may confer differences in Pellino specificity (Figures 1.3, 3.8). 
Performing mutational analyses of this β4/β5 loop in Pellinos will provide insight into whether this 
loop is not only important for substrate recognition, but also for the regulation of Pellinos. In 
addition, more in vitro studies are necessary to determine the changes in Pellino substrate 
specificity (if any) when mammalian Pellino family members are phosphorylated. 
 
4.4. Pellino substrate binding includes more than the recognition of a short pT-peptide 
sequence 
The discovery that R224 of the β9/β10 loop within the Pellino FHA core mediates interaction with 
substrate and not pT-peptide motifs suggests that there are other binding determinants that 
mediate Pellino substrate recognition. Future studies should look at whether these other binding 
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determinants enhance Pellino binding affinities as seen with the M. tuberculosis FHA domain-
containing FhaA protein, which interacts with its cognate binding partner, MviN, 2-fold stronger 
than a peptide library screen-optimized pT-peptide [35,59]. A feasible starting point would be to 
look at the Pellino2 binding to IRAK1-197. Large enough quantities of phosphorylated IRAK1-197 
can potentially be crudely purified from HEK293T lysates for more quantitative binding studies 
with Pellino2. We have tried to capture Xpress-tagged IRAK1-197 on an α-Xpress surface 
plasmon resonance (SPR) sensor chip, but the capturing conditions were not suitable for 
maintaining protein stability. In the future, these conditions need to be optimized in order for 
IRAK1-197 to be immobilized on a SPR sensor chip. Binding studies with longer IRAK1-derived 
pT peptides or pT peptides with more than one phosphorylation site may also be useful tools in 
further probing the molecular basis of Pellino substrate recognition.  
While we initially reasoned that the Pellino3a unique insertion acts as a phosphomimetic 
peptide that blocks the FHA domain pT-peptide binding pocket, we now cannot rule out the 
possibility that the insertion blocks some other part of Pellino3a such as the β9/β10 loop. The 
β9/β10 loop may be necessary for Pellino3b association with IRAK1 and RIP1, but not for 
TRAF6. This may explain why Pellino3a can only interact with TRAF6 (Figure 3.4C), yet Pellino3a 
and 3b have essentially the same pT+3 motif preferences. More mutational analyses are required 
to determine precisely how the Pellino3a insertion blocks IRAK1 and RIP1 binding. 
The FHA wing appendage is an extreme example of β-strand insertions that may mediate 
FHA domain specificity. Though we have not found any residues that are critical for IRAK1 
association, our mutational analysis of the FHA wing appendage did not take into account the fact 
that Pellino phosphorylation sites are mapped to the wing appendage (Figure 1.3) [45]. Thus, it is 
still entirely possible that the Pellino wing facilitates substrate interaction only when 
phosphorylated. Again, it will be important to elucidate whether Pellino phosphorylation is able to 
modulate substrate specificity; doing so will provide insight into the function of the Pellino wing 
appendage.  
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4.5. Parallels between FHA and SH2 domains may assist in elucidating Pellino substrate 
specificity 
Analogous to FHA domains, Src homology 2 (SH2) domains are phospho-binding modules that 
recognize phosphotyrosine (pY) in a sequence specific manner. Also similar to FHA domains, 
SH2 are capable of recognizing short phosphopeptide sequences. Directed pY-peptide library 
screens of SH2 domains have revealed SH2 peptide binding motifs in the same way that the 
pT+3 motifs were discovered for FHA domains [67]. Interestingly, various analyses on the peptide 
binding preferences of SH2 domains have shown that different SH2 domains can recognize the 
same peptide motifs with similar affinities in vitro [68]. As mentioned earlier, this is also the case 
for many FHA domains (including Pellinos) that are able to bind to the same Rad9p-derived 
peptide. We have also shown that while Pellinos have different substrate specificities, Pellinos 
can bind to the pT141 peptide variants within the same micromolar range. Thus, it remains 
elusive as to how FHA and SH2 domains are able to recognize cognate binding partners and 
discriminate against phosphorylated proteins that are not actual targets in vivo. The structure of 
the N-terminal SH2 domain of phospholipase Cγ in complex with the tyrosine kinase domain of 
FGFR1 reveals that there is a secondary binding site that facilitates SH2 domain selectivity and 
enhances binding affinity to FGFR1 [69]. Again, the presence of an additional binding determinant 
for SH2 domain recognition is a reflection of the FhaA:MviN interaction [59]. Since there are far 
more extensive studies on elucidating SH2 domain specificities and function, we should take into 
consideration the previous SH2 domain studies and design analogous experiments that can 
elucidate Pellino FHA domain specificity and function. The far western analysis and phosphatase 
protection assays used in this study were originally inspired by experiments performed on SH2 
domains [70,71]. Future studies should focus on emulating studies that were used to probe SH2 
domain specificity in a high-throughput manner and SH2 domain functions in vivo. 
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4.6. Probing the regulation and biological functions of Pellinos 
As alluded to in Chapter 1, gaining insight into Pellino substrate specificity will lead to a better 
appreciation of the roles that individual Pellinos play in orchestrating immune receptor signaling. 
Here, we suggest how our new studies can provide new tools to investigate the regulation and 
biological functions of Pellinos.  
Our results together with gene targeting studies in mice suggest that Pellinos mediate 
non-redundant roles in immune signaling, in part, by interacting with distinct substrates. An 
understanding of how Pellinos precisely mediate these divergent immune signaling pathways will 
require the identification of bona fide Pellino substrates. Despite the fact that the Pellino1 and 3 
knockout mice studies have identified novel signaling components that Pellinos regulate, it is not 
clear whether Pellino family members are directly or indirectly acting upon these signaling 
components. For instance, while Pellino1 has been shown to mediate TCR signaling by down-
regulating cRel [25], there is no evidence that Pellino1 directly interacts with and ubiquitinates 
cRel in vivo. Moreover, Pellino3 knockout mice studies have shown to disrupt the levels of TRAF6 
ubiquitination in vivo [21], but experiments have failed to detect Pellino3 directly polyubiquitinating 
TRAF6 in vitro. To help distinguish between Pellino binding partners or simply downstream 
signaling components, we propose to perform far western analyses similar to the setup that was 
used to study the Pellino2-IRAK1 interaction (Chapter 2).   
So far, only the FHA domain Pellno3 has been demonstrated to be essential for 
mediating proper immune signaling function and apoptosis [10,28]. While we have shown that 
disrupting the Pellino2 FHA domain pT-peptide binding pocket abrogates IRAK1 
polyubiquitination in a transfection model, it remains to be determined whether disrupting the 
Pellino2 FHA domain pT-peptide binding pocket will affect IRAK1 polyubiquitination and 
subsequently NF-κB activation in vivo. Moreover, it is unclear whether the Pellino1 FHA domain is 
required for modulating TRIF-mediated TLR signaling and T-cell activation. Future studies should 
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address the functional consequence of inhibiting the Pellino-substrate interaction by using Pellino 
variants with mutations that disrupt the FHA domain pT binding pocket. Our studies have 
introduced additional Pellino variants (Pellino2R224A and Pellino3a E54-66A) that should be 
pursued further to provide insight into the Pellino FHA domain-mediated regulation of immune 
signaling.  
Pellinos have now been shown to participate in a variety of immune signaling pathways. 
As many other E3 ubiquitin ligases are involved in the same signaling pathways, being able to 
specifically inhibit Pellino catalytic activity will be necessary to decouple irrelevant ubiquitination 
events that modulate immune processes from those that are Pellino-mediated. Since we have 
shown that Pellinos have different phosphothreonine motif specificities, using pT-peptides that 
block individual Pellino substrate-binding domains would be a novel way to inhibit Pellinos and 
explicitly probe different branches of signaling that are specific to Pellinos.  
 
4.7. Therapeutic prospects of targeting Pellinos 
As mentioned earlier, Pellinos are implicated in having both augmentative and protective effects 
on inflammatory diseases. Pellino1 is a critical mediator of microglia activation and contributes to 
the onset of the mouse model for multiple sclerosis, autoimmune encephalomyelitis (EAE) [29]. 
On the other hand, Pellino3 deficiency enhances the pathogenesis of experimental murine 
models of colitis [10]. The different Pellino substrate specificities can feasibly be exploited for 
pharmacological advantage in treating inflammatory diseases that have been recently linked to 
the aberrant regulation of Pellinos. 
As seen for a NEMO-binding domain peptide that blocks NFκB-activation and reduces 
tumor growth in a canine model of spontaneous diffuse large B-cell lymphoma [72], the use of 
high-affinity peptides to inhibit Pellino substrate binding and block Pellino-mediated immune 
signaling may be of therapeutic relevance. Here, we postulate how to make use of therapeutic 
peptides that target Pellinos. If indeed Pellino1 mediates the onset of multiple sclerosis in 
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patients, one could focus on developing a peptide or peptide mimetic that specifically interacts 
with and inhibits Pellino1. In this case, minimal interaction with Pellino3a and 3b would be 
necessary because Pellino3 isoforms may provide protection against Crohn’s disease. Now that 
both Pellino3 isoforms have been implicated in regulating TNFα-induced apoptosis [28], targeting 
Pellino3 can potentially be promising anti-cancer therapeutics. Only the Pellino3 FHA domain and 
not the catalytic RING domain is responsible for regulating TNFα-induced apoptosis [28]; thus, 
peptide-based inhibition can be a very specific way to block TNF signaling while preserving 
Pellino3 function in other immune signaling pathways. In order to develop a Pellino3-specific 
drug, one would first need to determine whether a peptide library screen-optimized pT-peptide 
binds to Pellino3 isoforms with high affinity. Since Pellinos most likely have redundant roles in 
regulating IRAK1-dependent pathways, peptides that target the entire family of Pellinos may be 
very useful as well. A starting point for an anti-inflammatory drug that binds to all Pellinos could 
be a peptide that contains a pTxxY motif.  
Our results on Pellino pT-peptide binding and substrate specificity strongly encourages 
the prospects of therapeutics that can be developed to specifically target an individual Pellino with 
minimal off-target effects. However, we are still very far away from pursuing a Pellino inhibitor. It 
still remains elusive whether disrupting the Pellino FHA domain has an effect on the onset or 
prevention of inflammatory disease states linked to the aberrant regulation of Pellinos; 
investigations in the near future should address this. Moreover, in order to determine if Pellinos 
would make good drug targets, future studies should probe the molecular basis of Pellino 
substrate specificity even further in hopes to better understand Pellinos’ roles in specific cellular 
processes and the pathogenesis of inflammatory diseases.  
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5. The molecular mechanisms of Pellino- and TRAF6-mediated ubiquitination of 
IRAK1 
Upon IL-1R/TLR stimulation, Pellinos and TRAF6 are the E3 ubiquitin ligases that are implicated 
in the K63-linked polyubiquitination of IRAK1 [13,20]. While Pellinos and TRAF6 target the same 
substrate, it remains unclear whether these two very different E3 ubiquitin ligases have distinct 
functional roles in the IL-1R/TLR signaling pathways. As seen with signaling components targeted 
by multiple ubiquitin ligases, IRAK1 may actually be subjected to the ubiquitin editing process that 
is common in NF-κB signaling [3] (see Figure 1.1 for a well-characterized example of ubiquitin 
editing on RIP1). When IRAK1 becomes activated by TLR/IL-1R stimulation, TRAF6, Pellinos and 
also SCF-β-TrCp E3 ubiquitin ligases may actually come together to form complexes involved 
with coordinating the different polyubiquitination linkages that have been previously reported for 
IRAK1 [73,74]. Gaining insight on the molecular basis of Pellino- and TRAF6-mediated 
ubiquitination of IRAK1 will elucidate the mechanisms by which these E3 ubiquitin ligases 
regulate IRAK1 and other substrates in immune signaling pathways. In this chapter, we describe 
attempts to determine the structure of the non-canonical Pellino RING domain and to investigate 
the molecular basis of TRAF6 association with IRAK1.  
   
5.1. Attempts to determine the structure of the non-canonical Pellino RING domain 
RING domains confer specificity for E2 ubiquitin ligases, which result in specific ubiquitin linkages 
on substrates [75]. The classical RING domain is defined as a conserved sequence of cysteines 
and histidines: C-X2-C-X(9–39)-C-X(1–3)-H-X(2–3)-C/H-X2-C-X(4–48)-C-X2-C (also known as the C3HC4 
motif) [75]. Intriguingly, Pellinos contain non-canonical RING domains, which have the cysteine 
and histidine pattern: Cys-X1-His-X19-Cys-X2-Cys-X30-Cys-X1-His-X25-Cys-X2-Cys (CHC2CHC2 
motif) [11]. A better understanding of the Pellino RING domain specificity for E2 ubiquitin ligases 
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will elucidate the type of linkages Pellinos can generate, thereby providing insight into Pellinos’ 
regulatory role in immune receptor signaling. Our goal was to solve the structures of (1) full-length 
Pellino2 in complex with E2 ubiquitin ligases and (2) more stable forms of full-length Pellinos 1 
and 2.  
 
5.1.1. Pellino2 does not interact with UbcH7 and Ubc13 
Full-length Pellino2 expressed and purified from E. coli undergoes rapid degradation of the C-
terminal RING domain resulting in a stable FHA-only fragment. This suggests that the Pellino 
RING domain in this E.coli-derived protein may be misfolded and/or intrinsically structurally 
disordered. We reasoned that in an E2 ubiquitin ligase-Pellino complex, the Pellino C-terminal 
RING domain would be stabilized by the interaction with the E2 ubiquitin ligase and protected 
from proteolysis. We chose to use the E2 ubiquitin ligases, UbcH7 and Ubc13, because the 
structures of these E2 ubiquitin ligases in complex with E3 ubiquitin ligases have been previously 
characterized [76,77]. In addition, Ubc13 in conjunction with E. coli-derived Pellinos 1 and 3b 
form K63-linked polyubiquitin chains in vitro even without the addition of IRAK1 [13]. Purified 
UbcH7 and Ubc13 were individually mixed with full-length Pellino2 and assayed for complex 
formation by size exclusion chromatography as was done with TRAF6 and Ubc13 [77]. Ubc13 
and UbcH7 do not co-elute on a gel filtration column (Figure 5.1A, B), which suggests that 
Pellino2 does not interact with these E2 ubiquitin ligases – suggesting that the KD values for 
interaction of Pellino2 with these E2 ubiquitin ligases is greater than one micromolar. We also 
assayed for Pellino2:Ubc13 interaction by performing a GST-Pellino2 pull-down, but also did not 
detect association with Ubc13 (Figure 5.1C). This is in contrast to the TRAF6-Ubc13 interaction 
where the KD value is measured to be 1.48µM [77]. Future studies should use other protein 
binding assays such as analytical ultracentrifugation sedimentation equilibrium to determine if 
there are protein-protein interactions at higher protein concentrations.  
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While we did not detect E2 ubiquitin ligase interaction with Pellino2, we only tested 2 out 
of the ~40 mammalian E2 ubiquitin ligases. Further studies should be tried to determine whether 
Pellino2 interacts with any of the E2 ubiquitin ligases that have been shown to form ubiquitin 
chains with Pellino1 [45]. However, caution must be taken when interpreting the results if Pellino2 
binding to these E2 ubiquitin ligases cannot be detected because IRAK1-catalyzed in vitro Pellino 
ubiquitination assays have failed to demonstrate actual IRAK1 ubiquitination [13,45]. We suspect 
that the E2 ubiquitin ligases used in these assays are not physiologically relevant.  
Further studies should also attempt to detect Ubc13 interaction with Pellino1 and 3b. It is 
possible that in addition to having different substrate specificities, Pellinos also have different E2 
ubiquitin specificities.  
5.1.2. E. coli-derived full-length Pellino1 is more stable than Pellino2 
Since the Pellino2 RING domain is sensitive to proteolysis, we attempted to crystallize full-length 
Pellino1, which is more stable when expressed and purified from E coli (Figure 5.2A, B). 
Crystallization screening attempts with Pellino1 are summarized in Table 5.1.  
When we tested full-length Pellino1 for pT-peptide binding, we found that Pellino1 
consistently bound to pT-peptides ~10 times tighter than Pellino1-FHA (Table 5.2). This is not 
expected because solely the FHA domain is presumed to be mediating interaction with 
phosphopeptides. These results suggest that Pellino1 RING domain may be directly involved with 
mediating phosphopeptide interaction, or may stabilize the Pellino1-FHA domain to optimize 
interaction with peptide. This is not observed for Pellino2, where the affinities for full-length 
Pellino2 and Pellino2-FHA binding to pT141+3S peptide are similar (Table 5.2). The peptide 
binding affinity differences we see between Pellino1-FHA, full-length Pellino1 and Pellino2 
reiterate that Pellinos have distinct substrate specificities. Why only the Pellino1 RING domain 
contributes to pT-peptide binding is hard to reconcile due to the fact the RING domains between 
the Pellinos also share high sequence identity. Future structural characterization of Pellino1 alone 
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or bound to pT-peptide will be needed to provide insight into the molecular basis of Pellino1 
substrate binding.  
5.1.3. Attempts to crystallize Sf9-derived Pellino2 
We also expressed Pellino2 in insect (Sf9) cells using the baculovirus expression system to test 
whether Pellino2 RING domain may be more stable when produced in an eukaryote. Pellino2 
expressed in Sf9 cells was not as sensitive to proteolysis and could be purified to homogeneity. 
Crystallization screening attempts with Pellino2 are summarized in Table 5.1. 
 As previously mentioned, E coli.-derived full-length Pellino2 is sensitive to C-terminal 
protein degradation. It is entirely possible that the reason we could not detect Pellino2 association 
with Ubc13 and UbcH7 is due to the C-terminal RING domain being misfolded. Thus, Sf9-derived 
Pellino2 should be assayed for E2 interaction. It will also be interesting to see whether the more 
stable insect cell expressed Pellino2 binds more tightly to pT-peptides than Pellino2-FHA, as we 
observed for E. coli expressed Pellino 1. 
 
5.2. Molecular basis of TRAF6 interaction with IRAK1 
5.2.1. TRAF6 interacts with the C-terminal domain of IRAK1 
Previous structural studies have shown that the TRAF6 substrate binding domain recognizes a P-
X-D-X-X-(aromatic/acidic residue) sequence motif known as the TRAF6 binding motif [78]. The 
IRAK1 C-terminal domain (Ct) contains three of these TRAF6 binding motifs (referred to as 
IRAK1 Ct motif 1-3, 1 being the most N-terminal). Mutations within these binding motifs in IRAK1 
disrupt TRAF6-mediated activation of the NF-κB. However, short IRAK1-derived peptides 
containing these individual TRAF6 binding motifs interact with TRAF6 with rather weak affinities 
(KD values of 50-500µM, Figure 5.3A). These observations led us to postulate that TRAF6 
association with IRAK1 may involve binding determinants additional to the TRAF6 binding motif, 
or may involve binding of multiple TRAF6 molecules to a single IRAK1 substrate.   
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To address this, we investigated the interaction of the TRAF6 substrate-binding domain 
(residues 346-504, TRAF6-C) with an IRAK1 Ct construct (residues 522-712) that contains all 
three putative TRAF6 binding motifs. We first employed surface plasmon resonance to determine 
the binding of TRAF6-C to IRAK1 Ct that had been amine coupled to a CM5 Biosensor chip. We 
found that TRAF6-C binds to IRAK1 Ct with a KD value of 6µM – a10-fold tighter affinity than 
previously reported for the strongest binding IRAK1-derived peptide (IRAK1 Ct motif 3; Figure 
5.3A,C). Ye et al also measured binding to peptides derived from the intracellular region of CD40 
(a TNF receptor family member). They report no difference in affinity for peptide of 9 and 30 
amino acids in length (centered on the TRAF6 motif; KD values of 59.9µM and 84µM, 
respectively) [78], suggesting that the low affinity for the 8-10 amino acid peptides is not simply 
due to the length. A number of factors may account for the higher affinity observed for interaction 
of TRAFA6 with IRAK Ct: the TRAF6 binding motifs may be presented in an optimal configuration 
in this larger protein domain; there may be additional contacts with TRAF6 involving parts of 
IRAK1 Ct outside the short TRAF6 binding motifs; and the increase in affinity may be due to the 
presence of multiple TRAF6 binding motifs in IRAK1 Ct. To distinguish between these two 
possibilities, future experiments should involve a mutational analysis of IRAK1 Ct and competitive 
IRAK1-derived peptide binding experiments.  
We have found the tightest binding yet for a TRAF6-substrate interaction (KD = 6µM). 
Elucidation of the TRAF6-IRAK1 interaction could potentially be advantageous for therapeutic 
modulation. TRANCE-R (another TNF receptor family member)-derived peptides that weakly bind 
to TRAF6 (KDs ≥ 78µM [78]) have already shown to specifically inhibit TRAF6 and block 
osteoclastogenesis [79]. However, further studies that investigate the molecular basis of TRAF6 
substrate binding should not overlook working with protein constructs as opposed to solely 
looking at peptide binding.   
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5.2.2. TRAF6 and IRAK1 bind with 2:1 stoichiometry 
The physiologically relevant stoichiometry of TRAF6 remains elusive. Structural studies have 
shown that the catalytic portion of TRAF6 (including the RING domain) forms a dimer when 
bound to Ubc13 [77]. Disruption of the TRAF6 dimerization interface abrogates TRAF6 catalytic 
activity in vitro [77]. However, the substrate binding domains of TRAF6 and other TRAF family 
members form trimmers in solution [78,80-82]. In addition, the oligomerization state of TRAF6 
when bound to substrates is unclear due to the fact that some known substrates have 1-3 
putative TRAF6 binding motifs and some substrates, including IRAK1, are known to dimerize.  
We sought to determine the stoichiometry of the TRAF6:IRAK1 complex. Again, we used 
the TRAF6-C construct, which has been reported to be monomeric in solution at micromolar 
concentrations [78]. Using sedimentation velocity analytical ultracentrifugation analyses, we find 
that IRAK1 Ct and TRAF6 sediment as simple monomeric species with sedimentation coefficients 
of 1.4 S and 1.9 S, respectively (Figure 5.4A). The molecular weights of both proteins are 20kDa, 
so the differences seen in sedimentation coefficients suggest differences in the hydrodynamic 
properties of the proteins. This is not surprising considering IRAK1 Ct is proline-rich and is 
predicted to be a disordered region of IRAK1. We therefore assume that IRAK1 Ct is not a 
globular protein. A mixture comprising of a 1:1 molar ratio of TRAF6-C and IRAK1 Ct shows two 
species with sedimentation coefficients of 1.6 S and 2.6 S. The smaller of these species has a 
sedimentation value close to that of IRAK1 Ct alone and likely represents unbound IRAK1 Ct. The 
larger species is consistent with formation of a species containing IRAK1 monomer bound to 
TRAF6-C.  
We then turned to sedimentation equilibrium analytical ultracentrifugation experiments to 
elucidate the TRAF6:IRAK1 stoichiometry. Sedimentation equilibrium data plotted as ln A280nm 
against the square of the radial position reveals a straight line with a slope proportional to the 
sample’s weight average molecular weight. TRAF6-C sediments as a 20kDa globular protein, 
indicating that it is a monomer at a protein concentration of 45µM (Figure 5.4B). Much like the 
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sedimentation velocity experiments, IRAK1 Ct sediments like a smaller protein compared to 
TRAF6-C, but in actuality, it is sedimenting as a non-globular protein. When we mix TRAF6-C 
and IRAK1 Ct in equimolar concentrations, the sample sediments as a 40kDa globular protein. 
However, a sample containing a 2:1 molar ratio of TRAF6-C to IRAK1 Ct sediments larger than 
40kDa globular protein. When we increase the amount of TRAF6-C to a 3:1 molar ratio of 
TRAF6-C and IRAK1 Ct, the size of the sedimenting species decreases to the size of the species 
in a 1:1 mixture. We presume that the 1:1 and 3:1 TRAF6-C:IRAK1Ct mixtures sediment 
approximately the same size because both mixtures have excess IRAK1Ct or TRAF6-C, which 
lowers the average molecular weight of the sample. These data suggest that TRAF6-C forms a 
2:1 complex with IRAK1 Ct. It is likely that the TRAF6 interacts with the second and third motifs in 
IRAK Ct and not with the first motif, which in the peptide binding studies bound TRAF6 with a 
much weaker affinity (KD = 518µM). We have purified an IRAK1 Ct construct that does not 
contain IRAK1Ct motif 1 (IRAK1CtS, residues 549-712), but this construct is not amenable to 
SPR binding experiments because it did not immobilize under the amine coupling conditions. 
Future studies should determine whether IRAK1CtS binds TRAF6-C with the same affinity as 
IRAK1Ct using other experimental means, such as isothermal titration calorimetry (ITC).  
In vivo FRET experiments of full-length TRAF6 suggest that upon LPS stimulation, 
TRAF6 forms high-order oligomers that can be visualized under the microscope [77]. The 
aggregation of TRAF6 could act as a functionally relevant scaffold for downstream signaling 
components. It would be interesting to determine the oligomeric state of full-length TRAF6 and 
IRAK1 and determine its relevance to IL-1/TLR signaling.  
 
5.3. Conclusion 
We have now elucidated the Pellino and TRAF6 binding determinants on IRAK1. Because their 
substrate binding specificities and RING domains are both quite different, we suspect that these 
E3 ubiquitin ligases do not play redundant roles in the IL-1/TLR signaling pathways. To gain a 
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better understanding of the distinct functional roles these E3 ubiquitin ligases play, future studies 
should compare the timing and location of TRAF6- and Pellino-mediated IRAK1 polyubiquination. 
One approach to do this would be to monitor the ubiquitination state of IRAK1 in the presence of 
cell-permeable TRAF6 or Pellino decoy peptides upon TLR/IL-1R stimulation. Furthermore, it 
would be insightful to figure out which E2 ubiquitin ligases interact with TRAF6 and Pellinos. It is 
possible that differences in IRAK1 polyubiquitination can lead to different interactions with 
downstream components that would in turn, lead to different cellular consequences. Pellino3 
have recently been shown to interact with and regulate TRAF6 in the context of the TLR3/4-
mediated IRF7 activation pathway [21]. It is possible that Pellinos act upon TRAF6 in a similar 
manner within the NF-κB activation pathway.  
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Figure 5.1 Pellino2 interactions with UbcH7 and Ubc13 are undetectable 
(A) Superimposed size exclusion chromatography profiles of Pellino2, Ubc13 or a 1:1 molar ratio 
mixture of the two proteins (5µM each). (B) Superimposed size exclusion chromatography 
profiles of Pellino2, UbcH7 or a 1:1 molar ratio mixture of the two proteins (5µM each). (C) GST 
or GST-Pellino2 immobilized to glutathione agarose beads were incubated with 10µM of Ubc13. 
Bound protein was eluted by SDS-PAGE loading buffer, analyzed by SDS-PAGE, and detected 
with Coomassie staining. “In” represents 5% input. In A-C, there is no detectable Pellino2 
association with the E2 ubiquitin ligases. 
 
 
  
  
71 
Figure 5.2. E. coli-derived Pellino1 and Sf9-derived Pellino2 are more stable than E. coli-
derived Pellino2.   
(A-C) Ni2+-NTA gravity flow chromatography fractions at the indicated imidazole concentrations of 
His6-tagged proteins analyzed by SDS-PAGE, and detected with Coomassie staining. (A) E. coli-
derived His6-Pellino2 is already partially proteolyzed after the first protein purification step. (B) E. 
coli-derived His6-Pellino1 is not as degraded as Pellino2 after the first protein purification step. (C) 
There appears to be minimal protein degradation with Sf9-derived His6-Pellino2. 
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Figure 5.3. TRAF6 interacts with IRAK1Ct 
(A) KD values for TRAF6-C binding to peptides derived from TRAF6 binding motifs on IRAK1 as 
determined by isothermal titration calorimetry (ITC). TRAF6 binding motifs on IRAK1 are 
numbered 1-3, starting from the most N-terminal motif. The asterisked binding data were obtained 
from [78]. (B) Domain architecture of TRAF6 and IRAK1 along with the constructs used in (C) and 
Figure 5.4. DD: death domain; PST: Proline, serine, threonine-rich region; Ct: C-terminal domain; 
Z1-4: TRAF6 zinc fingers; CC: coiled-coiled domain; TRAF: C-terminal TRAF6 substrate binding 
domain. The molecular weights of both IRAK1Ct and TRAF6-C are 20kDa. (C) SPR analysis of 
TRAF6-C binding to IRAK1 Ct. A series of samples of TRAF6-C at the indicated concentrations 
was passed over a CM5 chip to which IRAK1 Ct had been immobilized. The curve indicates the fit 
of a representative data set to a simple one-site binding equation. The KD value is 6.0µM.  
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Figure 5.4. TRAF6 and IRAK1 bind with an apparent 2:1 stoichiometry  
TRAF6-C, IRAK1Ct, or mixtures of both proteins were analyzed by sedimentation velocity (A) and 
sedimentation equilibrium (B) analytical ultracentrifugation. All experiments were conducted in 
12.5mM MES, 150mM NaCl, 2mM βME, 1mM TCEP. (A) Sedimentation velocity analytical 
ultracentrifugation analysis of 17µM of TRAF6-C, IRAK1Ct and a 1:1 mixture of TRAF6-C and 
IRAK1Ct (17µM each) by sedimentation coefficient distribution, c(s). (B) TRAF6-C (45µM) and 
IRAK1Ct (15µM) with or without increasing concentrations of TRAF6-C (15, 30, 45µM) were 
centrifuged at 20,000rpm. Sedimentation data are plotted as lnA280 against (r2  -  r02/2), where r is 
the radial position in the sample and r0 is the radial position of the meniscus. This representation 
gives a straight line with a slope proportional to the sample’s average molecular mass. The dotted 
lines represent simulated sedimentation equilibrium data for globular proteins at the specified 
molecular weights.    
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6. Methods 
 
6.1. Expression vectors 
All proteins are human homologs except for mouse Pellino1, which differs by only one amino acid 
from the human homolog (S146 is asparagine in human). The cDNA for RIP1 (Open Biosystems) 
was inserted into pcDNA4/HisMaxC (Invitrogen). IRAK1 in p3xFLAG-CMV-14 (Sigma) and 
pcDNA4/HisMaxC, Pellino2 and TRAF6 in pcDNA4/HisMaxC were generous gifts from Lisolette 
Jensen (Temple University, Pennsylvania). Expression plasmids for GST-Pellinos and His6-
Pellinos are described in [30]. The appropriate coding regions for truncated IRAK1 and Pellinos 
were inserted into pcDNA4/HisMaxC and into a pET21-derived HTUA vector (generously 
provided by Gregory Van Duyne, UPenn), respectively. The cDNA for Ubc13 and UbcH7 (Open 
Biosystems) were inserted into HTUA. The appropriate coding region for TRAF6-C-His6 was 
subcloned into the pET21 vector. The Quikchange site-directed mutagenesis strategy 
(Stratagene) was used for creating alterations in pcDNA4/HisMaxC-IRAK1-197, His6- and GST-
Pellinos. Full-length Pellino2 was subcloned into the pFastBacHT vector (Invitrogen); the Bac-to-
Bac expression system (Invitrogen) was then used for generation of recombinant baculovirus and 
for protein expression in Spodoptera frugiperda (Sf9) insect cells. 
 
6.2 Protein production and purification 
6.2.1. E. coli-derived protein production and purification 
GST- and His6-Pellino constructs, His6-Ubc13, His6-UbcH7, TRAF6-His6, and His6-IRAK1 
constructs, were expressed in E. coli BL21 (DE3) pLys cells at 37°C and induced with 0.5mM 
IPTG at 25°C for 3-6 hours. Afterwards, cells were pelleted and resuspended in lysis buffer 
(50mM HEPES, 300mM NaCl, 10% glycerol, pH 7) supplemented with 1mM phenylmethylsulfonyl 
fluoride (PMSF) and stored at -20°C until ready for use. Cells were thawed and kept at 4°C 
throughout the purification process unless otherwise noted, and were sonicated 3-5 times at 60% 
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amplitude for 20-30 seconds (1 second on, 1 second off). Cell lysates were then spun at 35,000g 
for 25-45 minutes to clear insoluble cellular debris.  
Glutathione agarose beads were incubated with cleared lysates containing GST-Pellinos 
for 30-90 minutes, washed 3 times in 3 bead volumes (BV) 50mM sodium phosphate, 300mM 
NaCl, pH 7.4, and resuspended in 20mM sodium phosphate, 150mM NaCl, pH 7.4 (PBS). To 
ensure addition of equal amounts of immobilized GST-proteins for pull-down assays, the amount 
of immobilized GST-proteins were visualized using SDS-PAGE and normalized with the addition 
of blank glutathione agarose beads.  
 Ni2+-NTA agarose beads were incubated with cleared lysates containing His6-tagged 
proteins for 30-90 minutes. The beads were then resuspended in 5-7 BV of wash buffer (25mM 
imidazole, 50mM Tris, 300mM NaCl, pH 8) and loaded onto a gravity flow column. Following an 
additional wash, His6-tagged proteins were eluted with duplicate 2 BV imidazole concentrations of 
50, 100, 150mM (with 50mM Tris, 300mM NaCl, pH 8). Imidazole elutions of 80-90% purity were 
pooled. To remove the His6-tag, His6-Pellino constructs, His6-IRAK1Ct constructs, His6-Ubc13, 
His6-UbcH7 were incubated with TEV protease [83] (~100µg for every 5mg of His6-tagged 
protein) and dialyzed overnight against various dialysis buffers.  
His6-Pellinos were dialyzed against 10mM HEPES, 300mM NaCl, and 5mM β-
mercaptoethanol (βME), pH 7.0. His6-Ubc13 and His6-UbcH7 were dialyzed against 10mM 
HEPES, 150mM NaCl, and 5mM βME, pH 7.0. TRAF6-C-His6 was dialyzed against 10mM MES, 
80-150mM NaCl, and 5mM βME, pH 6.5. Dialysis was performed overnight at 4°C for Pellino1 
and 2, His6-Ubc13, His6-UbcH7, and TRAF6-C-His6 at 22°C for Pellino3a and 3b. Digested, 
untagged Pellinos, Ubc13, and UbcH7, and TRAF6-C-His6 were buffer exchanged into ~80mM 
NaCl, 5mM βME, in the appropriate pH and purified by cationic exchange chromatography 
(Source S, GE Healthcare) at pH 6 (Pellinos1, 2 and 3b, Ubc13, UbcH7) or pH 5.5 (Pellino3a). 
His6-IRAK1Ct constructs were dialyzed overnight at 4°C against 10mM HEPES, 80mM NaCl, 
5mM βME, pH 7.5. TEV-digested, untagged IRAK1 Ct constructs were purified by anion 
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exchange chromatography (Source Q, GE Healthcare) at pH 7.5. Following ion exchange 
chromatography, protein fractions were pooled and further purified by size exclusion 
chromatography (Superose 12, GE Healthcare) in 10mM HEPES, 150mM NaCl, 5mM βME, pH 
7.0 (Pellino constructs, Ubc13, UbcH7, and IRAK1Ct constructs) or 10mM MES, 150mM NaCl, 
5mM βME, pH 6.5 (TRAF6-C-His). 
6.2.2. Sf9-derived Pellino2 production and purification 
Sf9 cells at 1.5–2×106/ml were infected with freshly amplified, recombinant baculovirus and 
harvested by centrifugation 3 days post infection. Sf9 cells expressing His6-Pellino2 were then 
resuspended in lysis buffer (50mM HEPES, 300mM NaCl, 10% glycerol, pH 7) supplemented 
with general protease inhibitor cocktail (Sigma) plus 1mM PMSF and stored at -20°C until ready 
for use. Subsequent purification steps of His6-Pellino2 were exactly the same as E. coli-derived 
protein.  
 
6.3. HEK293T culture conditions and transfections 
Human embryonic kidney (HEK) 293T cells were cultured in DMEM supplemented with 10% FBS, 
1% Pen-Strep, and 1% L-glutamine at 37°C, 5% CO2 and split 10-15-fold every 3-4 days. One 
day prior to transfection, 2.5x105 HEK293T cells were seeded per well in a 6-well plate. The next 
day, cells were at ~75% confluence and transected with 2µg of total DNA plus FuGENE6 
(Promega, 4.7µl FuGENE6 + 60µl DMEM per well in 6 well plate).   
 
6.4. GST-Pellino pull-down assays 
6.4.1. Pull-downs of Pellino substrates 
Two days post-transfection, HEK293T cells overexpressing IRAK1, IRAK1 truncation mutants, 
TRAF6, or RIP1 (all Xpress-tagged) were washed with PBS and lysed by vigorous scraping 
against the tissue culture dish in HEK293T lysis buffer (50mM HEPES pH 7.5, 150mM NaCl, 
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5mM βME, 0.1% IGEPAL [octylphenoxypolyethoxyethanol, Sigma], supplemented with 20mM β-
glycerophosphate, 1mM EDTA, 50mM NaF, 1mM Na3VO4, protease inhibitor cocktail [Sigma]). 
For HEK293T cells overexpressing RIP1, HEK293T lysis buffer was additionally supplemented 
with PhosSTOP (Roche). Lysates were subsequently kept at 4°C unless otherwise noted. After 
incubation for 20 minutes on ice, lysates were spun at 16,000g to clear cellular debris. Lysates 
were incubated with GST-Pellino proteins immobilized on glutathione agarose beads (50µl) for 4 
hours to overnight. Beads were washed 3 times with HEK293T lysis buffer and resuspended in 
SDS-PAGE loading buffer for western blot analysis.  
For dephosphorylation of IRAK1-197, HEK293T cells overexpressing Xpress-IRAK1-197 
were lysed in 50mM HEPES pH 7.5, 100mM NaCl, 10mM MgCl2, 5mM βME, 0.1% IGEPAL 
supplemented with protease inhibitor cocktail (Sigma) and incubated for 1 hour at 37°C with or 
without calf intestinal phosphatase (CIP, New England Biolabs; 10U/100µl of lysate). CIP 
treatment was stopped with 5mM EDTA and the addition of 1mM sodium vanadate or PhosSTOP 
(Roche).  
Western blots were probed with α-Xpress (Invitrogen) or α-phosphothreonine (pT, 
Invitrogen or Cell Signaling) and detection used horseradish peroxidase conjugated to α-mouse 
and α-rabbit (GE Healthcare), or IRDye680RD-α-rabbit and IRDye800CW-α-mouse (Li-COR 
Biosciences).  
6.4.2. Pull-down of Ubc13 
GST-Pellino immobilized to agarose beads was incubated with 200µl of 10µM Ubc13 in binding 
buffer (10mM HEPES, 150mM NaCl, 5mM βME) for 1 hour at 4°C. Beads were washed 3 times 
with binding buffer and proteins were eluted with SDS-PAGE buffer. Bound protein was eluted by 
60µl SDS-PAGE loading buffer, analyzed by SDS-PAGE, and detected with Coomassie staining. 
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6.5. Far western analyses 
HEK293T lysates overexpressing FLAG-IRAK1 were separated by SDS-PAGE, transferred to 
nitrocellulose membranes, and analyzed by western and far western blotting. α-FLAG (Sigma), α-
His4 (Qiagen), and α-pT (Invitrogen) were used for western blots. For far western blots, 
nitrocellulose membranes were incubated with 6ml of Pellino2 or Pellino2R106A (10µg/ml) in 
10mM HEPES, 150mM NaCl, 5mM βME, 0.3% bovine serum albumin (BSA) for 2 hours at 25°C. 
Far western blots were washed 3 times with 50mM Tris, 150mM NaCl, 0.05% Triton X-100 
(TBST) and subsequently probed with α-His4 as if performing a western blot.   
 
6.6. Peptide pull-down assays 
Peptides were synthesized using standard FMOC chemistry with free N-termini and purified by 
reverse-phase HPLC (made in the laboratory of P. Leslie Dutton, UPenn). The purity and 
molecular mass were confirmed by MALDI time-of-flight mass spectrometry. The following 
peptides were made: IRAK1-derived peptides WVRDQpTELRL; SGQRpTASVLW; 
WSPGTpTAPRP; WISRGpTHNFSE; TVRGpTLAY; Rad9-derived peptides: WSLEVpTEADT 
(Rad9pT192); WSLEVTEADT (Rad9T192). Some experiments used the Rad9p peptide 
YSLEVpTEADT, which was purchased from Bio Basic Inc. Lyophilized HPLC-purified peptides 
were resuspended in DMSO and amine coupled to Affi-Gel 15 agarose beads (Bio-Rad) 
according to the manufacturer's protocol. Peptide-coupled beads were equilibrated with binding 
buffer (25 mM HEPES, 300 mM NaCl, and 1 mM DTT, pH 7.0). For each pull-down reaction, 100 
µl of Pellino1, 2, 3b, Pellino2-FHA (residues 15-275) or Pellino2 R106A (50 µM, in binding buffer) 
was incubated with 20 µl peptide-coupled beads for 1 hour at 4°C. The beads were washed three 
times with binding buffer supplemented with 0.1% Triton X-100. Bound protein was eluted by 40µl 
SDS-PAGE loading buffer, analyzed by SDS-PAGE, and detected with Coomassie staining. 
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6.7. Isothermal titration calorimetry 
Pellino2-FHA and pT141+3S peptide used in the ITC experiment were dialyzed overnight into 25 
mM HEPES pH 7.0, 150mM NaCl, 5mM βME at 4°C. Protein and peptide solutions were 
quantified by UV spectrophotometry. Extinction coefficients for proteins were determined by 
Protein Calculator v3.3 (http://www.scripps.edu/~cdputnam/protcalc.html). The ITC experiment 
was performed using an ITC200 microcalorimeter (MicroCal Inc). pT141+3S peptide (275µM) 
was titrated into a sample cell containing Pellino2-FHA (25µM) in 16 serial injections at 20°C. 
Experimental data was analyzed using ORIGIN software as per the manufacturer’s instructions.  
 
 6.8. IRAK1 dephosphorylation protection assay 
HEK293T cells transfected with Xpress-IRAK1 were lysed with HEK293T lysis buffer. Cleared 
lysates were first incubated with protein G agarose (Invitrogen) for 1 hour at 4°C to remove 
proteins that non-specifically interact with protein G agarose beads. IRAK1 was 
immunoprecipitated from the lysates by using IRAK1 antibody (Santa Cruz Biotechnologies) and 
protein G agarose beads overnight. IRAK1 immobilized onto beads were washed with wash 
buffer (50mM HEPES, 150mM NaCl, 5mM βME, pH 7.5) and then treated with or without 
Antarctic phosphatase (AP, 5U per reaction) in the presence of Pellino2 (1µM) in Antarctic 
phosphatase (AP) reaction buffer (wash buffer supplemented with 1mM MgCl2 and 0.1mM ZnCl2) 
for 45 minutes at 37°C with gentle agitation. After 1 wash with wash buffer, IRAK1 was then 
eluted from protein G agarose by denaturation, separated by SDS-PAGE, and visualized by 
immunoblotting. Xpress-antibody was used to visualize IRAK1, pT-antibody was used to visualize 
phosphorylated threonines, and detection used horseradish peroxidase conjugated to α-mouse 
and α-rabbit (GE Healthcare). 
 
  
82 
6.9. Detection of IRAK1 polyubiquitination 
Xpress-Pellino2, and FLAG-IRAK1 (2µg of DNA total) was transfected into HEK293T cells. Cells 
were lysed 1 day after transfection. Cleared lysates were first incubated with protein G agarose 
(2.5µl, Invitrogen) for 20 minutes at 4°C to remove proteins that non-specifically interact with 
protein G agarose beads. IRAK1 was immunoprecipitated from the lysates by using IRAK1 
antibody (Santa Cruz Biotechnologies) and protein G agarose beads (20µl) overnight. Beads 
were washed 3 times with HEK293T lysis buffer and resuspended in SDS-PAGE loading buffer 
for western blot analysis. Western blots were probed with α-Xpress (Invitrogen) and α-ubiquitin 
(Dako); detection used horseradish peroxidase conjugated to α-mouse and α-rabbit (GE 
Healthcare).  
 
6.10. Fluorescence polarization peptide binding assays 
C-terminally amidated peptides were purchased from Bio Basic Inc., AnaSpec, or Keck 
Biotechnology Resource Laboratory (Yale University). These peptides were N-terminally labeled 
with fluorescein-5-isothiocyanate (FITC) or 5,6-Carboxyfluorescein (5,6-FAM) by the 
manufacturer, or in-house. For in-house labeling, amine-reactive FITC (Invitrogen) dissolved in 
DMSO (10mg/ml) was added to peptide in 0.1M sodium bicarbonate at pH 9.0 (~10mg/ml). The 
reaction was constantly stirred for 60-120 minutes at room temperature. To remove excess FITC 
label, the reaction was spun through a BioSpin6 (Bio-Rad) column pre-equilibrated in PBS.  
Due to the light-sensitivity of fluorescein, peptides’ exposures to light were kept to a 
minimum. Peptide binding reactions (100µl) contained 50nM fluorescein-labeled peptide plus 
increasing concentrations of Pellinos (0-190µM) in PBS. Fluorescence polarization for each 
sample was measured using a Beacon 2000 system (Panvera) –use of which was generously 
provided by Prof. Gregory Van Duyne (UPenn). Data were fitted to a simple binding isotherm 
using Prism (GraphPad Software). All fluorescence polarization (mP) values were normalized to 
the mP value from no added Pellino. For binding experiments with low affinity peptides, protein 
  
83 
concentrations did not reach maximum specific polarization (Bmax), so data fitting required a 
constrained Bmax; the constrained Bmax values used were from Bmax values obtained from 
experiments with the same Pellino proteins binding to IRAK1-derived pT141+3S peptide.   
 
6.11. Protein X-ray crystallography 
6.11.1. Pellino:peptide co-crystallization screening 
Peptides (>99.5% purity) that were used in crystallization studies were dissolved and dialyzed 
against 10mM HEPES pH 7 and 80mM NaCl for 2-3 days at 4°C to ensure removal of 
trifluoroacetic acid (TFA). The IRAK1pT141 long peptide (IRAK1pT141L) has the following 
sequence: YKLPSSASpTFLSPAFP (Bio Basic Inc.). The pH of the peptides was always checked 
to ensure the TFA had been fully removed. Gel filtration fractions of Pellino1, Pellino2, and 
truncation variants were pooled, concentrated, and buffer exchanged into 10mM HEPES pH 7, 
75mM NaCl and reducing agent [5mM βME, 1mM dithiothreitol (DTT), or 2mM tris(2-
carboxyethyl)phosphine (TCEP)]. Concentrated proteins were mixed with 200-1000µM peptides 
in varying ratios to make up 10mg/ml of total protein. The Mosquito Crystal (TTP Labtech) was 
used to set up 96-well hanging-drop crystal screens: 100µl of screening conditions were 
dispensed into 96 well plate, 100-300nl of ~10mg/ml protein were mixed with 200-400nl of 
reservoir solution and equilibrated over 100µl of reservoir solution at 20°C.  
 
6.11.2. Peptide soaking of Pellino2 crystals 
Expression and purification methods for Pellino2-FHAV61M/L232M are exactly the same as Pellino2-
FHA. Gel filtration fractions of Pellino2-FHAV61M/L232M were pooled, concentrated, and buffer 
exchanged into 10mM HEPES pH 7, 75mM NaCl and 5mM βME. Pellino2-FHAV61M/L232M was 
crystallized using the hanging-drop vapor diffusion method. Equal volumes of Pellino2-
FHAV61M/L232M (10mg/ml) and reservoir solution (100mM sodium acetate pH 4.6 or 4.8 and 3.25M 
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sodium formate) were mixed and equilibrated over the reservoir solution at 20°C. 2µl of 8.5% 
glutaraldehyde was placed next to the drop containing crystals and the drops were left to 
equilibrate with reservoir for 10-15 minutes until the protein started precipitating from drops 
containing crystals. Precipitation caused the transfer of cross-linked crystal to be very tedious, so 
alternatively, crystals would be transferred to stabilization solution (reservoir plus 5% ethylene 
glycol) prior to crosslinking. Cross-linked crystals were transferred into cryoprotectant [reservoir 
solution plus ~150mM pT141+3Y peptide, supplemented with either 6% glycerol, 6% ethylene 
glycol, 6% 2-methyl-2,4-pentanediol (MPD) or 7.5% PEG 400, 7.5% PEG 1000] for 1-5 minutes. 
The cross-linked crystals were flash frozen from cryoprotectant. Data were collected at the 
Advanced Photon Source GM/CA 23-ID-B beam line. Data were processed with HKL-2000 [84] 
and solved by molecular replacement in the program PHASER [57]. The canonical FHA core of 
the Pellino2-FHA structure (PDB ID: 3ega) was used as a search model. 
 
6.11.3. Pellino3a-FHA protein crystallization and structure determination 
For the spontaneous crystallization of Pellino3a-FHA, gel filtration fractions of Pellino3a-FHA 
were pooled, concentrated to ~9mg/ml (300µl), and incubated in a 1.5ml microcentrifuge tube at 
4°C for ~6 weeks. Pellino3a-FHA crystals also formed by the hanging drop vapor diffusion by 
setting up 1-5µl drops of Pellino3a-FHA (6-10mg/ml) and equilibrating over gel filtration buffer 
(10mM HEPES pH 7, 150mM NaCl, 5mM βME) at 20°C. Pellino3a-FHA at high protein 
concentrations (>6mg/ml) was very sensitive to spontaneous nucleation so precautionary steps 
were taken to reduce the amount of nucleations: concentrating small volumes of protein at a time 
(~30µl final concentrated volume); keeping highly concentrated, 0.22µM filtered Pellino3a-FHA at 
20°C; using low-retention 1.5ml microcentrifuge tubes; changing pipet tips after setting up each 
crystallization drop; keeping pipet tip direct contact with tube and cover slip surfaces at a 
minimum; setting up drops as quickly as possible. To improve X-ray diffraction of these Pellino3a-
FHA crystals, we also tried dehydrating crystals. Crystals were transferred to 1-2µl drops 
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containing 10mM HEPES pH 7, 150mM NaCl, and 5mM βME with or without 10-15% ethylene 
glycol. The drops were equilibrated with the same solution in the reservoir for ~16 hours at 20°C.  
For other crystallization conditions using the hanging drop vapor diffusion method, equal 
amounts of Pellino3a-FHA (6-10mg/ml) were mixed with and equilibrated over reservoir solutions 
at 20°C. We also attempted to control crystal growth by crystal seeding into lower concentrations 
of Pellino3a-FHA. A Pellino3a-FHA crystal (~70µm3 in size) was transferred to 75mM HEPES pH 
7, 600mM sodium tartrate, 5% ethylene glycol and crushed with a seed bead (Hampton) as per 
the manufacturer’s instruction. A 1:1000 dilution of crushed Pellino3a-FHA crystals was streak-
seeded into Pellino3a (2.8-8.5mg/ml) and reservoir solution (75mM HEPES pH 7, 600mM sodium 
tartrate) mixed in equal volumes and equilibrated over reservoir solution at 20°C.  
All crystals were cryoprotected by adding gel filtration buffer supplemented with 66% 
ethylene glycol until the concentration of ethylene glycol reached ~33% and directly flash frozen 
from the drop. Data was collected at the Advanced Photon Source GM/CA 23-ID-B beam line. 
Data was processed with HKL-2000 [84] and was solved by molecular replacement (MR) in the 
program PHASER [57]. The canonical FHA core of the Pellino2-FHA structure (PDB ID: 3ega) 
was used as a search model. 
6.11.4. Pellino1 and 2 full length crystal screening 
Gel filtration fractions of Pellino1 and 2 were pooled, concentrated, and buffer exchanged into 
10mM HEPES pH 7, 75mM NaCl and reducing agent (5mM βME, 1mM DTT, or 2mM TCEP). 
Hanging drops for crystallization screens were set up exactly like the Pellino:peptide co 
crystallization screens. Crystallography screening trays were incubated at 4°C or 20°C.  
 
6.12. Surface plasmon resonance binding experiments 
SPR experiments were performed on a Biacore3000 instrument (GE healthcare) at 25°C in 
25mM HEPES, 150mM NaCl, 3 mM EDTA, 0.005% Tween-20, pH 7.5. The hydrogel matrix of a 
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Biacore CM5 biosensor chip was activated with N-ethyl-N’-(dimethylaminopropyl)-carbo-diimide 
hydrochloride and N-hydroxysuccinimide. IRAK1Ct (100µg/ml in 10 mM sodium acetate, pH 4.5) 
was flowed over this activated surface at a rate of 5 µl/min for 7 minutes. The remaining reactive 
sites were blocked with 1 M ethanolamine-HCl (pH 8.5). The signal contributed by immobilized 
IRAK1 constructs ranged from 1100-1850 response units (RUs). TRAF6 binding response values 
are reported after reference (mock-coupled surface binding) subtraction. Data were analyzed 
using Prism (GraphPad). 
 
6.13. Analytical ultracentrifugation experiments 
Sedimentation velocity and sedimentation equilibrium analytical ultracentrifugation experiments 
were performed in a Beckman Optima XL-A instrument, at 20°C in 12.5mM MES, 150mM NaCl, 
2mM βME, 1mM tris(2-carboxyethyl)phosphine (TCEP).  Absorbance at 280  nm was measured to 
detect protein distribution. For sedimentation velocity experiments, 17µM of TRAF6, IRAK1Ct or a 
1:1 molar ratio mixture of both proteins were centrifuged at 42500 rpm, at 20°C in 12.5mM MES, 
150mM NaCl, 2mM βME, 1mM TCEP. Continuous distributions were calculated by c(s) analysis 
in SEDFIT (http://www.analyticalultracentriguation.com) using solution and protein property 
estimates from SEDNTERP (http://www.jphilo.mailway.com). For sedimentation equilibrium 
experiments, TRAF6-C (45µM) and IRAK1Ct (15µM) with or without increasing concentrations of 
TRAF6-C (15, 30, 45µM) were centrifuged at 10,000, 15,000, and 20,000 rpm. Data were 
analyzed with SEDFIT and SEDPHAT (http://www.analyticalultracentriguation.com). 
Sedimentation equilibrium data were plotted as lnA280 against (r2  -  r02/2), where r is the radial 
position in the sample and r0 is the radial position of the meniscus. This representation gives a 
straight line with a slope proportional to the average molecular mass of the sample. 
HeteroAnalysis [85] was used to simulate sedimentation equilibrium data for 20, 40, 60, and 
80kDa globular proteins.   
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